<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413699</url>
  </required_header>
  <id_info>
    <org_study_id>A3921024</org_study_id>
    <secondary_id>2006-005035-19</secondary_id>
    <nct_id>NCT00413699</nct_id>
  </id_info>
  <brief_title>Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis</brief_title>
  <official_title>A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the long-term effectiveness and safety of
      CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study
      only after participating in another &quot;qualifying&quot; study of CP-690,550

      A sub-study will be conducted within the A3921024 study, this study will evaluate the immune
      response to pneumococcal and influenza vaccines in patients receiving CP-690,550
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2007</start_date>
  <completion_date type="Actual">October 26, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports</measure>
    <time_frame>Includes laboratory test abnormality data for all visits and adverse event data up to 999 days after last dose of study drug</time_frame>
    <description>Treatment-emergent non serious AEs by System Organ Class (SOC) (all causalities) and Laboratory Test Abnormalities (without regard to baseline) The stated number of participants analyzed was the total number of participants in each group (AEs). The actual number of participants analyzed for each laboratory parameter varied, and is provided for each.
Abs=absolute; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ESR=erythrocyte sedimentation rate; GGT=gamma glutamyl transferase; hgb=hemoglobin; HDL=high density lipids; LDL=low density lipids; LLN=lower limit of normal; qual=qualitative; Tot=total; ULN=upper limit of normal; WBC=white blood cell</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Long-term Safety and Tolerability of CP-690,550 5 Milligrams (mg) Twice Daily (BID) and 10 mg BID for the Treatment of Rheumatoid Arthritis</measure>
    <time_frame>Includes AEs for every visit and up to 999 days after last dose of study drug</time_frame>
    <description>Treatment-emergent AEs by SOC (all causalities) - all participants, by time. Data presented for Post Month 96 includes data up to and including Month 114.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With American College of Rheumatology (ACR) 20, 50, and 70 Responses</measure>
    <time_frame>Every visit until study completion</time_frame>
    <description>The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
ACR20 is defined as a 20% improvement from baseline in tender/painful joint count and swollen joint count, and at least 3 of the following 5 variables: Subject's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, Subject's Assessment of Arthritis Pain, Health Assessment Questionnaire - Disability Index, C-Reactive Protein (CRP).
ACR50 is a 50% improvement and ACR70 a 70% improvement in these variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under American College of Rheumatology (ACR) n Curve</measure>
    <time_frame>Not applicable as no data were collected for this endpoint.</time_frame>
    <description>No data were collected for this endpoint because it was removed from the protocol in a previous amendment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS)28 (C-reactive Protein [CRP]) and DAS28 (Erythrocyte Sedimentation Rate [ESR])</measure>
    <time_frame>Every visit until study completion</time_frame>
    <description>Descriptive statistics for DAS28-3 (CRP) and DAS28-4 (ESR). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula.
The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of &gt;5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of &lt;2.6 indicates disease remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) of Participants With DAS28-4 (ESR) and DAS28-3 (CRP) &lt;2.6 and ≤3.2</measure>
    <time_frame>Every visit until study completion</time_frame>
    <description>Percent participants with DAS28-4 (ESR) &lt;2.6 and ≤3.2 and percent participants with DAS28-3 (CRP) &lt;2.6 and ≤3.2. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula.
The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of &gt;5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of &lt;2.6 indicates disease remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire - Disability Index (HAQ-DI) Score</measure>
    <time_frame>Every visit until study completion</time_frame>
    <description>Change from baseline by visit. HAQ-DI scores range from 0 to 3, where lower score implies less disease. A reduction from baseline in score indicates an improvement in condition. A clinically meaningful decrease from baseline is defined as a decrease of at least 0.22 units.
The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form-36 Health Survey (SF-36) Score</measure>
    <time_frame>Every visit until study completion</time_frame>
    <description>Change from Baseline for Physical Component and Mental Component Scores by visit. SF-36 is a health status measure of 8 general health domains, each scored on a 0 to 100 scale: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These domains can be summarized as physical and mental component scores. The domain scores were &quot;normed&quot; and the resulting component scores treated as Z-scores with a scale of negative to positive infinity. A higher score implies less disease. The greater the change from baseline, the greater the improvement. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACIT Fatigue Scale, EuroQol EQ 5D, Work Limitations Questionnaire, and RA Healthcare Resource Utilization Questionnaire (RA-HCRU)</measure>
    <time_frame>Every visit until study completion</time_frame>
    <description>Change from Baseline Scores for each: FACIT Fatigue Scale (score range 0 to 52, higher score indicates higher quality of life and an increase from baseline score indicates improvement), EuroQol EQ 5D (index values derived from a measure of central tendency and a measure of dispersion, an increase from baseline indicates improvement, score range 0 to 1), Work Limitations (WL) Physical Demands (covers ability to perform job tasks that involve bodily strength, a decrease from baseline indicates improvement, score range 0 to 100, higher scores indicating greater limitation), and RA Healthcare Resource Utilization Work Performance in Past 3 Months on Days Bothered by RA (assesses healthcare use over previous 3 months, a decrease from baseline indicates improvement, score range 0 to 10).
The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preservation of Joint Structure in Participants Who Had Baseline Radiographs Obtained in Their Qualifying Index Study</measure>
    <time_frame>Every 6 months until study completion</time_frame>
    <description>Modified Total Sharp Score per visit. Baseline score was the last available assessment from the index study. The Modified Total Sharp Score measures disease progression; increased scores indicate disease progression. Score range 0 (normal) to 448 (worst possible total score). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
TSS=Total Sharp Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Pneumococcal Vaccine as Defined by ≥ 2-fold Increase in Antibody Concentrations</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Seasonal Influenza Vaccine as Defined by ≥ 4-fold Increase in Antibody Titers</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Number of participants achieving a satisfactory humoral response to the seasonal influenza vaccine as defined by ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Percentage of Participants Achieving Protective Antibody Titers to the Seasonal Influenza Vaccine as Measured by a Hemagglutination Inhibition (HI) Assay Titer of ≥ 1:40 in ≥ 2 of 3 Influenza Antigens at Vaccine Sub-study Visit 3 and 4</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Number (%) of participants achieving protective antibody titers to the seasonal influenza vaccine as measured by an HAI assay titer of ≥1:40 in ≥2 of 3 influenza antigens measured at vaccine sub-study visits 3 and 4.
The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 12 Pneumococcal Antigens as Defined by ≥ 2-fold Increase in Antibody Concentrations From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 3 Influenza Antigens as Defined by ≥ 4-fold Increase in Antibody Titers From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Number (%) of participants achieving a satisfactory humoral response to the seasonal influenza vaccine defined as ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2).
The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Fold Increase of Anti-pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Geometric Mean Fold Increase From Baseline of Pneumococcal Antigens Measured at Visit 4.
n was the number of participants with valid and determinate assay results for the specified serotype at the given visit.
The stated number of participants analyzed was the total number of participants. The actual number of participants analyzed for some serotypes varied, and is provided where it differed from the total number of participants.
Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Fold Increase of Anti-influenza Antibody Levels to Each of the 3 Influenza Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Geometric Mean Fold Increase From Baseline of Influenza Antigens Measured at Visit 4.
n was the number of participants with valid and determinate assay results for the specified HAI strain at the given visit.
Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Concentrations of Anti-pneumococcal Antibodies at Vaccine Sub-study Visit 3 and 4</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Mean pneumococcal concentrations (ug/mL) at vaccine baseline (visit 2) and post-vaccination visits (visits 3 and 4) by serotype. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed for each serotype varied, and is provided for each individually.
ug/mL=micrograms per milliliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Sub-study. Titers of Anti-influenza Antibodies at Vaccine Sub-study Visit 3 and 4</measure>
    <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
    <description>Mean influenza antibody titers at visits 3 and 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4481</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Open-Label Active Treatment Enrolled from Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolling from Phase 2 studies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Active Treatment Enrolled from Phase 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolling from Phase 3 studies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.</description>
    <arm_group_label>Open-Label Active Treatment Enrolled from Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.</description>
    <arm_group_label>Open-Label Active Treatment Enrolled from Phase 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have participated in a randomized &quot;qualifying&quot; study of CP-690,550 for
             the treatment of rheumatoid arthritis

        Vaccine sub-study visit

          -  Subjects actively participating in Study A3921024 must have completed at least 3
             months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by &gt;80%
             compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.

        Exclusion Criteria:

          -  Serious medical conditions that would make treatment with CP-690,550 potentially
             unsafe

        Vaccine sub-study visit

          1. Any documented influenza or pneumococcal infection within the last 3 months prior to
             randomization in this study

          2. Received any vaccine within 1 month prior to randomization in this study

          3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years
             of randomization in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of North Alabama, PC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthrocare, Arthritis Care &amp; Research, PC</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P.C.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Pointe Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI St. Vincent Medical Group Hot Springs</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEA Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osborne Research Center, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Diagnostic Clinic, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Investigations, Inc.</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Talbert Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Center for Innovative Therapy</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Medicine of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC) Norris Comprehensive Cancer Center-</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC) Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center, Drug Information Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Anupama Bhat, MD</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Arthritis Medical Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Center Medical Group</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Health Services - Medical Specialty Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials, Inc.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Medical Center, PC</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates and Osteoporosis Center of Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-5353</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Center, PC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates, LLC</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Arthritis and Osteoporosis Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma, Arthritis, &amp; Lung</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Research Alliance LLC</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Arthritis Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Imaging and Diagnostics</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Integrated Medical PL d/b/a Florida Medical Research Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Integrated Medical, PL, d/b/a Florida Medical Research Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Arthritis Center, P.L.</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BayCare Outpatient Imaging at Bardmoor</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Arthritis and Rheumatic Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey Alper MD Research</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research, Inc.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Rheumatology Research Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jeffrey E. Poiley, MD , Office of</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DMI Research, Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Arthritis &amp; Osteoporosis Center</name>
      <address>
        <city>Port Richey</city>
        <state>Florida</state>
        <zip>34668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Medical Center</name>
      <address>
        <city>Port Richey</city>
        <state>Florida</state>
        <zip>34668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Medical Clinic</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatic Care Center</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Broward Rheumatology Associates, Inc.</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BayCare Medical Group, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venice Arthritis Center</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic, P.A.</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatology of Georgia P.C.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey D. Lieberman, MD, PC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Rheumatology Associates</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Clinic - Rheumatology</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Clinic</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Intermountain Research Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Clinic - Rhematology</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Bone and Joint Institute, LLC</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Health Physicians</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61103-3692</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Orthopedic Associates</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Clinic - Clinical Research</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deerbrook Medical Associates</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Rheumatology And Research PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician's Clinic of Iowa, P.C.</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Clinic, PC</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Internal Medicine</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Clinic, P.A.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Community Research, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation - Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates, MD, PA</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Treatment Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Cape Cod, Inc.</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reliant Medical Group, Inc.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reliant Medical Group, Inc. at Worcester Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Internal Medicine and Rheumatology</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institiute</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Research Institute</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmbrook Radiology Associates</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatology Consultants, P.A.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Clinics, Inc.</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Physicians - Woodrail Clinic</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Missouri-Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Massachusetts</city>
        <state>Nebraska</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westroads Clinical Research, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Clinic Research, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of North Jersey</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis, Rheumatic &amp; Back Disease Associates</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology, LLP</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Rheumatology Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Tier Arthritis and Rheumatism</name>
      <address>
        <city>Olean</city>
        <state>New York</state>
        <zip>14760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo Rheumatology and Medicine, PLLC</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAIR Research Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville Rheumatology &amp; Osteoporosis Research Associates, P.A.</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville Rheumatology &amp; Osteoporosis Research Associates, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research Hickory, LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Hickory</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>USA 28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boice-Willis Clinic</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Health Center - Medical Arts</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Rheumatic Disease Study Group, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of David R. Mandel, MD, Inc.</name>
      <address>
        <city>Mayfield</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation (OMRF)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology Associates, PC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Associates, Ltd.</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading LLP</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Arthritis Clinic, PA</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates, PLLC</name>
      <address>
        <city>Hixson</city>
        <state>Tennessee</state>
        <zip>37343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Consultants, PLLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909-1907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of John P. Lavery, MD, PA</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Rheumatology Research, PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Care and Diagnostic Center, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Texas Health Science Center at Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Associates, LLP</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology Research, LLC</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Seattle Arthritis Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Center of Arthritis Research, PS</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic, Inc. PS</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain State Clinical Research</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Clinic, Ltd</name>
      <address>
        <city>Onalaska</city>
        <state>Wisconsin</state>
        <zip>54650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OMI- Organizacion Medica de Investigacion</name>
      <address>
        <city>Buenos Aires</city>
        <state>Caba</state>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Reumatologicas y Osteologicas -CIRO</name>
      <address>
        <city>Buenos Aires</city>
        <state>Caba</state>
        <zip>C1114AAH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sirio Libanes</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1419AHN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OMI - Organización Médica de Investigación</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Dennis Medical Group S.A.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1034ACO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sirio Libanes</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1419AHN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios Reumatologicos Pampa</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428DZF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimus Clinical Research Pty. Ltd.</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Unit Sunshine Coast</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital, Department of Rheumatology</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goatcher Clinical Research Unit</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>WA 6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <zip>NSW2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien / AKH</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma-Ordination Favoriten</name>
      <address>
        <city>Wien</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sozialmedizinisches Zentrum Sued - Kaiser Franz Josef Spital</name>
      <address>
        <city>Wien</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent - Reumatologie</name>
      <address>
        <city>Gent</city>
        <state>Oost-vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIP - Centro Internacional de Pesquisa</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos em Terapias Inovadoras</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos em Terapias Inovadoras</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Alemao Oswaldo Cruz</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01323-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC-FMUSP)</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMA Brasil -Instituto de Pesquisa Clinica e Medicina Avancada</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologichen kabinet, DKTs Sveti Pantaleimon OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologichno Otdelenie, MBAL - Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMBAL Kaspela Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL Akta Medika OOD</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Cardiology and Rheumatology Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Rheumatology Multiprofile Hospital for Active treatment Sveti Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL Sveti Ivan Rilski Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DKTs &quot;Sveta Anna&quot; Sofia, Konsultativen kabinet po Revmatologia</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DKTs &quot;Sveta Anna&quot;, Sofia / Diagnostic Consultative Center &quot;Sveta Anna&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MOBAL &quot;D-r Stefan Cherkezov&quot; AD,</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Associates Ltd.</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Alice Klinkhoff, Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Percuro Clinical Research Limited</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. William G. Bensen Medicine Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Fernando Bianchi</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cividino Medicine Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KW Musculoskeletal Research Inc.</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 5N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Health Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology</name>
      <address>
        <city>Missisauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Program Research Group Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Osteoporosis Clinic</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Associates</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Peninsula Arthritis Centre</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2N 7E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research and Arthritis Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Rhumatologie de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Island Rheumatology Research Associates</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Musculo-Squelettique</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research Center, Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Saint-Louis</name>
      <address>
        <city>Quebec</city>
        <zip>G1W4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulta Privada Dra. Lucia Ponce</name>
      <address>
        <city>Temuco</city>
        <state>IX Region</state>
        <zip>4790928</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnostico y Tratamiento Hospital San Borja Arriaran</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>8360156</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Base Valdivia, Policlinico de Reumatologia</name>
      <address>
        <city>Valdivia</city>
        <state>Region XIV</state>
        <zip>5090145</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Reumatologicos</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7501126</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulta Privada Dra. Marta Aliste</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Santa Maria, Seccion Reumatologia</name>
      <address>
        <city>Providencia</city>
        <state>Santiago, RM</state>
        <zip>7530206</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Rancagua</name>
      <address>
        <city>Rancagua</city>
        <zip>2841959</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Santa Maria</name>
      <address>
        <city>Santiago</city>
        <zip>7530206</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Estudios Clinicos V Region</name>
      <address>
        <city>Vina Del Mar, V Region</city>
        <zip>2520997</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital, Capital University of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Centre-south University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, The Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QiLu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital/Rheumatology and Immunology Department</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Si Chuan Huaxi Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Province Hospital</name>
      <address>
        <city>Hefei</city>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>An Hui Medical University 1st Hospital</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Immunology Dept., Renji Hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Department of Infectious Diseases &amp; Immunology</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Reumatologia y Ortopedia S.A.S.</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A.</name>
      <address>
        <city>Bogota D.C.</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S CIREEM S.A.S</name>
      <address>
        <city>Bogota, D.C.</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servimed S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Reumatologia y Osteoporosis, Cartago</name>
      <address>
        <city>Cartago</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cima San Jose</name>
      <address>
        <city>San Jose</city>
        <zip>00000</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cima San Jose</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oficina Privada Del Colegio deMedicos</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Split, Department for Internal Medicine, Division of Clinical Rheumatology</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital &quot;Sveti Duh&quot;</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center &quot;Zagreb&quot;</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>X-MEDICA s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmacentrum MUDr. Mostera, s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>615 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno, Interni hematoonkologicka klinika</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HESTE s.r.o. Revmatologie</name>
      <address>
        <city>Ceska Lipa</city>
        <zip>470 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDIPONT Plus sro</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.K.N. Arthrocentrum, s.r.o.</name>
      <address>
        <city>Hlucin</city>
        <zip>748 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTMEDI UPD s r.o</name>
      <address>
        <city>Hostivice</city>
        <zip>253 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Ostrava</city>
        <zip>70800</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTHROMED, s. r. o. Revmatologicka ambulance</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affidea Praha, s.r.o.</name>
      <address>
        <city>Praha 11 - Chodov</city>
        <zip>148 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <zip>12850</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Thomayerova nemocnice s poliklinikou</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuselska poliklinika RTG</name>
      <address>
        <city>Praha 4</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Praha 4</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Atlas, a.s.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-Medical s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de las Fuerzas Armadas</name>
      <address>
        <city>Santo Domingo</city>
        <zip>10119</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingin Reumakeskus Oy</name>
      <address>
        <city>Helsinki</city>
        <zip>00120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiljavan Laaketutkimus Oy</name>
      <address>
        <city>Hyvinkaa</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TAYS/Reumakeskus/Finn-Medi 1</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>*CHR Hopital Porte Madeleine IPROS</name>
      <address>
        <city>Orleans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR ORLEANS - Service IPROS</name>
      <address>
        <city>Orleans</city>
        <zip>45032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privat-Praxis</name>
      <address>
        <city>Aachen</city>
        <zip>52064</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Mitte, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schlosspark-Klinik Innere Medizin II, Rheumatologie</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulantes Rheumazentrum Dr Soerensen</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Friedrichstadt, I. Medizinische Klinik</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienambulanz Universitaetsklinikum Erlangen Medizinische Klinik 3</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.W.-Goethe-Universitaetsklinik, Medizinische Klinik II, Abteilung fuer Rheumatologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis Rheumatologie</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schoen Klinik Hamburg-Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln Klinik I fuer Innere Medizin, Haus 16, 1. OG, Raum 1.008</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Leipzig, Klinik fur Gastroenterologie und Rheumatologie, Sektion Rheumatologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen, Campus Innenstadt, Rheuma-Einheit</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arztpraxis, Internist - Rheumatologie</name>
      <address>
        <city>Nuernberg</city>
        <zip>90429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumaforschung- Studienambulanz</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Rheumatologie</name>
      <address>
        <city>Rheine</city>
        <zip>48431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Euromedica &quot;KYANOUS STAVROS&quot;</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>424 General Army Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Research Center Kft</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Reumatologiai Es Fizioterapias Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Reumatologiai Rendelo</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>H-1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAV Korhaz es Rendelointezet, Reumatologiai szakrendeles</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahavir Hospital &amp; Research Center</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Diseases Clinic</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shalby Hospitals</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chanre Rheumatology and Immunology Center and Research</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College and Hospital.</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shirdi Sai Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chanre Rheumatology &amp; Immunology Center &amp; Research</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 079</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research and Care Foundation Centre for Rheumatic Diseases</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Centre Pvt. Ltd.</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences Ltd</name>
      <address>
        <city>Secunderabad</city>
        <state>Telangana</state>
        <zip>500 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Elm Park</city>
        <state>Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi - SOD Medicina Interna 1 e Reumatologia</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Clinica Reumatologica</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>Incheon</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Republic OF Korea</state>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul,</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center-University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital-Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital-The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tuanku Ja'afar</name>
      <address>
        <city>Seremban</city>
        <state>Negeri Sembilan</state>
        <zip>70300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunway Medical Centre</name>
      <address>
        <city>Petaling Jaya</city>
        <state>Selangor</state>
        <zip>46150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Subang Jaya Medical Centre</name>
      <address>
        <city>Subang Jaya</city>
        <state>Selangor</state>
        <zip>47500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Putrajaya, Dept. of Medicine</name>
      <address>
        <city>Putrajaya</city>
        <state>Wilayah Persekutuan</state>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion del Noroeste</name>
      <address>
        <city>Tijuana</city>
        <state>BAJA California Norte</state>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Enfermedades Reumaticas y Cronico Degenerativas SC</name>
      <address>
        <city>Torreon</city>
        <state>Coahuila</state>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles del Pedregal</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Toluca</name>
      <address>
        <city>Metepec</city>
        <state>Estado DE Mexico</state>
        <zip>52140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral en Reumatologia, SA de CV</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion en Enfermedades Cronico Degenerativas</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica Especializada, SC</name>
      <address>
        <city>Coyoacan</city>
        <state>Mexico D.F.</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica de Morelia</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Enfermedades Cronicas y Procedimientos Especiales SC</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58249</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion El Hospitalito</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62170</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Reumatologica Las Americas SCP</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigacion y Biomedica de Chihuahua, SC</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles Mocel</name>
      <address>
        <city>Mexico, D.F.</city>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Reumatologico Queretaro</name>
      <address>
        <city>Queretaro</city>
        <zip>76178</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central Dr Ignacio Morones Prieto Unidad Regional de Reumatologia y Osteoporosis</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Canterbury Geriatric Medical Research Trust, c/- The Princess Margaret Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8022</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital, Rheumatology</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Unit, Timaru Hospital</name>
      <address>
        <city>Timaru</city>
        <zip>7910</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional IV Alberto Sabogal Sologuren</name>
      <address>
        <city>Callao</city>
        <zip>C-02</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Corpac/Investigaciones en Reumatologia</name>
      <address>
        <city>Lima</city>
        <zip>L-27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Peruano del Hueso y la Articulacion SAC-Privado-Lima/Centro de Investigacion IPHAR</name>
      <address>
        <city>Lima</city>
        <zip>L-27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Mediatrix Medical Center</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle University Health Sciences Campus Clinical Epidemiology Unit</name>
      <address>
        <city>Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angeles University Foundation Medical Center</name>
      <address>
        <city>Angeles City</city>
        <state>Pampanga</state>
        <zip>2009</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chong Hua Hospital</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Philippine Medical Center</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Perpetual Help Rizal Dalta Medical Center</name>
      <address>
        <city>Las Piñas City</city>
        <zip>1742</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;ZDROWIE OSTEO-MEDIC&quot; s.c. Lidia I Artur Racewicz, Agnieszka I Jerzy Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Badurski i wspolnicy Spolka Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NSZOZ Medicus II</name>
      <address>
        <city>Cieszyn</city>
        <zip>43400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital im. Teodora Dunina</name>
      <address>
        <city>Koscian</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne NZOZ</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych s.c. Wieslawa Porawska, Lukasz Porawski</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Zespol Reumatologiczny im. dr Jadwigi Titz-Kosko</name>
      <address>
        <city>Sopot</city>
        <zip>81-759</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz &quot;Nasz Lekarz&quot;</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddzial w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma-Medicus - Specjalistyczne Centrum Reumatologii i Osteoporozy</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SYNEXUS Polska Sp. z.o.o.</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School Of Medicine</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edificio Parra</name>
      <address>
        <city>Ponce</city>
        <zip>00717-1321</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mindful Medical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic &quot;Sf. Maria&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic De Recuperare</name>
      <address>
        <city>Iasi</city>
        <zip>700661</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 1</name>
      <address>
        <city>Novosibirsk City</city>
        <state>Novosibirsk Region</state>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Consultative Diagnostic Rheumatology Center &quot;&quot;Healthy Joints&quot;&quot;, LLC&quot;</name>
      <address>
        <city>Novosibirsk City</city>
        <state>Novosibirsk Region</state>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution City Hospital # 40 of Administrative Health Resort District</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sestroretsk, Russia</state>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical Academy</name>
      <address>
        <city>Smolensk</city>
        <state>Smolensk Region</state>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Regional Clinical Hospital</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education Ural State Medical Academy of Federal</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd.Medical Association &quot;Novaya Bolnitsa&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620219</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Regional Clinical Hospital for War Veterans</name>
      <address>
        <city>Kemerovo</city>
        <zip>650099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian State Medical University Moscow Faculty City Clinical Hospital #4</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Institute of Russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ Republican Hospital n.a. Baranov</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal North-West Medical Research Centre</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Healthcare Institution &quot;Clinical Rheumathology Hospital #25&quot;</name>
      <address>
        <city>St. Petersburg,</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital #122 named after L.G. Sokolov of the Federal Medical-Biological Agency</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Institution of Healthcare Consultative-diagnostic Center #85</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198260</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Budget Institution Of Healthcare</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Budgetary Healthcare Institution of Tomsk Regional Clinical Hospital</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologicka ambulancia, Poliklinika Ruzinov</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOVAPHARM s.r.o -Zeleznicna NaP, Reumatologicka ambulancia</name>
      <address>
        <city>Bratislava</city>
        <zip>832 99</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAGS, s.r.o. , nestatne zdravotnicke zariadenie</name>
      <address>
        <city>Dunajska Streda</city>
        <zip>92901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interna a reumatologicka ambulancia</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ecclesia, s.r.o Reumatologicka ambulancia</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny Ustav Reumatickych Chorob</name>
      <address>
        <city>Piestany</city>
        <zip>92112</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologicka ambulancia, MUDr. Zuzana Cizmarikova, s.r.o.</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologicka ambulancia, REUMEX, s.r.o.</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>979 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologicka ambulancia, Nestatne zdravotnicke zariadenie</name>
      <address>
        <city>Senica</city>
        <zip>905 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nestatna reumatologicka ambulancia, MUDr. Pavol Polak s.r.o.</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Senora de la Esperanza</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruna</state>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Merida</name>
      <address>
        <city>Merida</city>
        <state>Badajoz</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruna</name>
      <address>
        <city>Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario De La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil. Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital El Tomillar</name>
      <address>
        <city>Sevilla</city>
        <zip>41700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falu lasarett</name>
      <address>
        <city>Falun</city>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lanssjukhuset Ryhov</name>
      <address>
        <city>Jonkoping</city>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus i Malmo Reumamottagningen</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundsvalls Sjukhus</name>
      <address>
        <city>Sundsvall</city>
        <zip>851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-</name>
      <address>
        <city>Niao Sung Hsiang</city>
        <state>Kaohsiung County</state>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Linkou Branch</name>
      <address>
        <city>Kwei-Shan</city>
        <state>Taoyuan County</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit, Department of Internal Medicine, Phramongkutklao Hospital</name>
      <address>
        <city>Rajathevee</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine,</name>
      <address>
        <city>Amphoe Mueang</city>
        <state>Chiang MAI</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Allergy-Immunology-Rheumatology, Department of Medicine, Faculty of Medicine</name>
      <address>
        <city>Muang District</city>
        <state>Khonkaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crimean Republican Institution &quot;Clinical Territorial Medical Association &quot;University Clinic&quot;,</name>
      <address>
        <city>Simferopol</city>
        <state>Crimea</state>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Establishment of Health Care &quot;Kharkiv City Clinical Hospital #8&quot;, Dept. of Rheumatology</name>
      <address>
        <city>Kharkiv</city>
        <zip>61178</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution Republican Clinical Hospital of the Ministry of Health of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Establishment &quot;Institute of Gerontology of NAMS of Ukraine n.a. D.F. Chebotareva&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal City Clinical Hospital #4, Policlinic Care</name>
      <address>
        <city>Lviv</city>
        <zip>79011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Multifield Medical Center of Odesa National Medical University &quot;&quot;University Clinic #1&quot;&quot;&quot;</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multifield Medical Center of Odesa National Medical University &quot;University Clinic #1&quot;</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRIMEAN Republican Institution, &quot;Clinical Hospital n.a. M.O. Semashko&quot;</name>
      <address>
        <city>Simferopol Crimea</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnitsa Regional Clinical Hospital n.a. Pirogov</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Establishment &quot;City Hospital#7of Zaporizhzhia State Medical University</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dudley Group of Hospitals NHS Trust</name>
      <address>
        <city>Dudley</city>
        <state>WEST Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Trust</name>
      <address>
        <city>Cannock</city>
        <zip>WS11 5XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wirral University Teaching Hospital NHS Foundation Trust-Arrowe Park Hospital</name>
      <address>
        <city>Wirral</city>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Dominican Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>United States Minor Outlying Islands</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921024&amp;StudyName=Long-Term%20Effectiveness%20And%20Safety%20Of%20CP-690%2C550%20For%20The%20Treatment%20Of%20Rheumatoid%20Arthritis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <results_first_submitted>November 17, 2017</results_first_submitted>
  <results_first_submitted_qc>February 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2018</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>long-term</keyword>
  <keyword>open-label</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 414 sites globally.</recruitment_details>
      <pre_assignment_details>Participants had previously participated in qualifying studies.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
          <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
        </group>
        <group group_id="P2">
          <title>Tofacitinib 10 mg BID</title>
          <description>Participants with average total daily dose across study &gt;/=15 were assigned to 10 mg BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1123"/>
                <participants group_id="P2" count="3358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="484"/>
                <participants group_id="P2" count="1653"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="639"/>
                <participants group_id="P2" count="1705"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication error without adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="211"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="527"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event not related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="248"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing end of study page</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="368"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
          <description>Participants with non-zero average daily dose across study &lt;15 were assigned to 5 mg BID</description>
        </group>
        <group group_id="B2">
          <title>Tofacitinib 10 mg BID</title>
          <description>Participants with average total daily dose across study &gt;/=15 were assigned to 10 mg BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1123"/>
            <count group_id="B2" value="3358"/>
            <count group_id="B3" value="4481"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="916"/>
                    <measurement group_id="B2" value="2838"/>
                    <measurement group_id="B3" value="3754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="520"/>
                    <measurement group_id="B3" value="727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="927"/>
                    <measurement group_id="B2" value="2744"/>
                    <measurement group_id="B3" value="3671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="614"/>
                    <measurement group_id="B3" value="810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports</title>
        <description>Treatment-emergent non serious AEs by System Organ Class (SOC) (all causalities) and Laboratory Test Abnormalities (without regard to baseline) The stated number of participants analyzed was the total number of participants in each group (AEs). The actual number of participants analyzed for each laboratory parameter varied, and is provided for each.
Abs=absolute; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ESR=erythrocyte sedimentation rate; GGT=gamma glutamyl transferase; hgb=hemoglobin; HDL=high density lipids; LDL=low density lipids; LLN=lower limit of normal; qual=qualitative; Tot=total; ULN=upper limit of normal; WBC=white blood cell</description>
        <time_frame>Includes laboratory test abnormality data for all visits and adverse event data up to 999 days after last dose of study drug</time_frame>
        <population>For abnormal laboratory results, those listed include both mandatory and optional laboratory tests. The number of participants analyzed is the number with at least one evaluable observation of the given laboratory test. Fasting lipids were only collected from participants who enrolled more than 14 days after last visit of their qualifying study.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports</title>
          <description>Treatment-emergent non serious AEs by System Organ Class (SOC) (all causalities) and Laboratory Test Abnormalities (without regard to baseline) The stated number of participants analyzed was the total number of participants in each group (AEs). The actual number of participants analyzed for each laboratory parameter varied, and is provided for each.
Abs=absolute; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ESR=erythrocyte sedimentation rate; GGT=gamma glutamyl transferase; hgb=hemoglobin; HDL=high density lipids; LDL=low density lipids; LLN=lower limit of normal; qual=qualitative; Tot=total; ULN=upper limit of normal; WBC=white blood cell</description>
          <population>For abnormal laboratory results, those listed include both mandatory and optional laboratory tests. The number of participants analyzed is the number with at least one evaluable observation of the given laboratory test. Fasting lipids were only collected from participants who enrolled more than 14 days after last visit of their qualifying study.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with non-serious AEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="991"/>
                    <measurement group_id="O2" value="2963"/>
                    <measurement group_id="O3" value="3954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="395"/>
                    <measurement group_id="O3" value="554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="185"/>
                    <measurement group_id="O3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congenital, familial and genetic disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and labyrinth disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="259"/>
                    <measurement group_id="O3" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                    <measurement group_id="O2" value="1011"/>
                    <measurement group_id="O3" value="1404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders and admin site conditions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="477"/>
                    <measurement group_id="O3" value="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune system disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="704"/>
                    <measurement group_id="O2" value="2200"/>
                    <measurement group_id="O3" value="2904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, poisoning and procedural complications</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                    <measurement group_id="O2" value="721"/>
                    <measurement group_id="O3" value="965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402"/>
                    <measurement group_id="O2" value="995"/>
                    <measurement group_id="O3" value="1397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="562"/>
                    <measurement group_id="O3" value="746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425"/>
                    <measurement group_id="O2" value="1314"/>
                    <measurement group_id="O3" value="1739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms benign, malignant and unspecified</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="219"/>
                    <measurement group_id="O3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="639"/>
                    <measurement group_id="O3" value="861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pregnancy, puerperium and perinatal conditions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Product issues</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="280"/>
                    <measurement group_id="O3" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive system and breast disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="206"/>
                    <measurement group_id="O3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="634"/>
                    <measurement group_id="O3" value="842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="682"/>
                    <measurement group_id="O3" value="883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social circumstances</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical and medical procedures</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="468"/>
                    <measurement group_id="O3" value="675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants evaluable for lab abnormalities</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1118"/>
                    <measurement group_id="O2" value="3346"/>
                    <measurement group_id="O3" value="4464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with laboratory abnormalities</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="3358"/>
                    <count group_id="O3" value="4481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1095"/>
                    <measurement group_id="O2" value="3208"/>
                    <measurement group_id="O3" value="4303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell count &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1049"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes (Abs) &lt;0.5x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="570"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="645"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes (Abs) &gt;1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="570"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="645"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets &lt;0.5x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1116"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets &gt;1.75x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1116"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocyte count (%) &lt;0.5x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocyte count (%) &gt;1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count &lt;0.6x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count &gt;1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Abs) &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254"/>
                    <measurement group_id="O2" value="789"/>
                    <measurement group_id="O3" value="1043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Abs) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (%) &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1043"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401"/>
                    <measurement group_id="O2" value="1267"/>
                    <measurement group_id="O3" value="1668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (%) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1043"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tot neutrophils (Abs) &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="305"/>
                    <measurement group_id="O3" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tot neutrophils (Abs) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="617"/>
                    <measurement group_id="O3" value="856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (%) &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1042"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (%) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1042"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (Abs) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (%) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1043"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="221"/>
                    <measurement group_id="O3" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (Abs) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (%) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1043"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (Abs) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (%) &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1043"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="405"/>
                    <measurement group_id="O3" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR &gt;1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1113"/>
                    <count group_id="O2" value="3343"/>
                    <count group_id="O3" value="4456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="872"/>
                    <measurement group_id="O2" value="2411"/>
                    <measurement group_id="O3" value="3283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin &gt;1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin &gt;1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1088"/>
                    <count group_id="O2" value="3344"/>
                    <count group_id="O3" value="4432"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect bilirubin &gt;1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1041"/>
                    <count group_id="O2" value="3344"/>
                    <count group_id="O3" value="4385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt;3.0x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3344"/>
                    <count group_id="O3" value="4461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;3.0x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT &gt;3.0x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase &gt;3.0x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen &gt;1.3x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine &gt;1.3x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol &gt;1.3x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1104"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4449"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol &lt;0.8x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1097"/>
                    <count group_id="O2" value="3301"/>
                    <count group_id="O3" value="4398"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol &gt;1.2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1094"/>
                    <count group_id="O2" value="3293"/>
                    <count group_id="O3" value="4387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides &gt;1.3x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1096"/>
                    <count group_id="O2" value="3300"/>
                    <count group_id="O3" value="4396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="373"/>
                    <measurement group_id="O3" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium &lt;0.95x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium &gt;1.05x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium &lt;0.9x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium &gt;1.1x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride &lt;0.9x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride &gt;1.1x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium &lt;0.9x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1041"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium &gt;1.1x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1041"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (venous) &lt;0.9x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="277"/>
                    <measurement group_id="O3" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (venous) &gt;1.1x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1117"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose &lt;0.6x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose &gt;1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1118"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="345"/>
                    <measurement group_id="O3" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase &gt;2.0x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1041"/>
                    <count group_id="O2" value="3345"/>
                    <count group_id="O3" value="4386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="908"/>
                    <measurement group_id="O3" value="1111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-reactive protein &gt;1.25x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="697"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="939"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine specific gravity &lt;1.003</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1098"/>
                    <count group_id="O2" value="3319"/>
                    <count group_id="O3" value="4417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine specific gravity &gt;1.030</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1098"/>
                    <count group_id="O2" value="3319"/>
                    <count group_id="O3" value="4417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="303"/>
                    <measurement group_id="O3" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH &lt;4.5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1098"/>
                    <count group_id="O2" value="3319"/>
                    <count group_id="O3" value="4417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH &gt;8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1098"/>
                    <count group_id="O2" value="3319"/>
                    <count group_id="O3" value="4417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine glucose (qual) ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1095"/>
                    <count group_id="O2" value="3319"/>
                    <count group_id="O3" value="4414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine ketones (qual) ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="686"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine protein (qual) ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1097"/>
                    <count group_id="O2" value="3319"/>
                    <count group_id="O3" value="4416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="222"/>
                    <measurement group_id="O3" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine blood/hgb (qual) ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1098"/>
                    <count group_id="O2" value="3319"/>
                    <count group_id="O3" value="4417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="444"/>
                    <measurement group_id="O2" value="1260"/>
                    <measurement group_id="O3" value="1704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine leukocyte esterase ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="687"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="819"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine red blood cells ≥20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="678"/>
                    <count group_id="O2" value="1498"/>
                    <count group_id="O3" value="2176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="491"/>
                    <measurement group_id="O3" value="689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine WBC ≥20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="689"/>
                    <count group_id="O2" value="1603"/>
                    <count group_id="O3" value="2292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="507"/>
                    <measurement group_id="O3" value="726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine epithelial cells ≥6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine casts &gt;1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="420"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine granular casts &gt;1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine hyaline casts &gt;1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine bacteria &gt;20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Long-term Safety and Tolerability of CP-690,550 5 Milligrams (mg) Twice Daily (BID) and 10 mg BID for the Treatment of Rheumatoid Arthritis</title>
        <description>Treatment-emergent AEs by SOC (all causalities) - all participants, by time. Data presented for Post Month 96 includes data up to and including Month 114.</description>
        <time_frame>Includes AEs for every visit and up to 999 days after last dose of study drug</time_frame>
        <population>The stated number of participants analyzed is the total number of participants enrolled in each group. The number of evaluable participants is the number remaining in the study in the given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>The Long-term Safety and Tolerability of CP-690,550 5 Milligrams (mg) Twice Daily (BID) and 10 mg BID for the Treatment of Rheumatoid Arthritis</title>
          <description>Treatment-emergent AEs by SOC (all causalities) - all participants, by time. Data presented for Post Month 96 includes data up to and including Month 114.</description>
          <population>The stated number of participants analyzed is the total number of participants enrolled in each group. The number of evaluable participants is the number remaining in the study in the given time period.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluable for AEs at Months 0 to 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1123"/>
                    <measurement group_id="O2" value="3358"/>
                    <measurement group_id="O3" value="4481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 0 to 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="61.8"/>
                    <measurement group_id="O3" value="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 0 to 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 6 to 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1033"/>
                    <measurement group_id="O2" value="3121"/>
                    <measurement group_id="O3" value="4154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 6 to 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 6 to 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 12 to 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="969"/>
                    <measurement group_id="O2" value="2865"/>
                    <measurement group_id="O3" value="3834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 12 to 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="46.8"/>
                    <measurement group_id="O3" value="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 12 to 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable at Months 18 to 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="896"/>
                    <measurement group_id="O2" value="2660"/>
                    <measurement group_id="O3" value="3556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 18 to 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 18 to 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 24 to 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820"/>
                    <measurement group_id="O2" value="2461"/>
                    <measurement group_id="O3" value="3281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 24 to 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="44.5"/>
                    <measurement group_id="O3" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 24 to 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 30 to 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774"/>
                    <measurement group_id="O2" value="2288"/>
                    <measurement group_id="O3" value="3062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 30 to 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0"/>
                    <measurement group_id="O2" value="40.7"/>
                    <measurement group_id="O3" value="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 30 to 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 36 to 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729"/>
                    <measurement group_id="O2" value="2162"/>
                    <measurement group_id="O3" value="2891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 36 to 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 36 to 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 42 to 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="652"/>
                    <measurement group_id="O2" value="1843"/>
                    <measurement group_id="O3" value="2495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 42 to 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="34.3"/>
                    <measurement group_id="O3" value="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 42 to 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 48 to 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558"/>
                    <measurement group_id="O2" value="1471"/>
                    <measurement group_id="O3" value="2029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 48 to 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 48 to 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 54 to 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466"/>
                    <measurement group_id="O2" value="1172"/>
                    <measurement group_id="O3" value="1638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 54 to 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1"/>
                    <measurement group_id="O2" value="35.4"/>
                    <measurement group_id="O3" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 54 to 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 60 to 66</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="918"/>
                    <measurement group_id="O3" value="1332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 60 to 66</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="31.4"/>
                    <measurement group_id="O3" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 60 to 66</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 66 to 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                    <measurement group_id="O2" value="670"/>
                    <measurement group_id="O3" value="1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 66 to 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="21.6"/>
                    <measurement group_id="O3" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 66 to 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 72 to 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336"/>
                    <measurement group_id="O2" value="262"/>
                    <measurement group_id="O3" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 72 to 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6"/>
                    <measurement group_id="O2" value="22.5"/>
                    <measurement group_id="O3" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 72 to 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 78 to 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 78 to 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="26.7"/>
                    <measurement group_id="O3" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 78 to 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 84 to 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 84 to 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 84 to 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs at Months 90 to 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs at Months 90 to 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="29.4"/>
                    <measurement group_id="O3" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs at Months 90 to 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluable for AEs post Month 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent with AEs post Month 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="46.7"/>
                    <measurement group_id="O3" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent discontinued due to AEs post Month 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With American College of Rheumatology (ACR) 20, 50, and 70 Responses</title>
        <description>The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
ACR20 is defined as a 20% improvement from baseline in tender/painful joint count and swollen joint count, and at least 3 of the following 5 variables: Subject's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, Subject's Assessment of Arthritis Pain, Health Assessment Questionnaire - Disability Index, C-Reactive Protein (CRP).
ACR50 is a 50% improvement and ACR70 a 70% improvement in these variables.</description>
        <time_frame>Every visit until study completion</time_frame>
        <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With American College of Rheumatology (ACR) 20, 50, and 70 Responses</title>
          <description>The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
ACR20 is defined as a 20% improvement from baseline in tender/painful joint count and swollen joint count, and at least 3 of the following 5 variables: Subject's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, Subject's Assessment of Arthritis Pain, Health Assessment Questionnaire - Disability Index, C-Reactive Protein (CRP).
ACR50 is a 50% improvement and ACR70 a 70% improvement in these variables.</description>
          <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR20 at Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1114"/>
                    <count group_id="O2" value="3307"/>
                    <count group_id="O3" value="4421"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.65"/>
                    <measurement group_id="O2" value="73.60"/>
                    <measurement group_id="O3" value="72.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1080"/>
                    <count group_id="O2" value="3254"/>
                    <count group_id="O3" value="4334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.81"/>
                    <measurement group_id="O2" value="76.06"/>
                    <measurement group_id="O3" value="75.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1069"/>
                    <count group_id="O2" value="3228"/>
                    <count group_id="O3" value="4297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.68"/>
                    <measurement group_id="O2" value="78.00"/>
                    <measurement group_id="O3" value="77.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1040"/>
                    <count group_id="O2" value="3132"/>
                    <count group_id="O3" value="4172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.58"/>
                    <measurement group_id="O2" value="77.36"/>
                    <measurement group_id="O3" value="76.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1003"/>
                    <count group_id="O2" value="3022"/>
                    <count group_id="O3" value="4025"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.57"/>
                    <measurement group_id="O2" value="77.53"/>
                    <measurement group_id="O3" value="77.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="972"/>
                    <count group_id="O2" value="2891"/>
                    <count group_id="O3" value="3863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.88"/>
                    <measurement group_id="O2" value="78.24"/>
                    <measurement group_id="O3" value="78.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="938"/>
                    <count group_id="O2" value="2775"/>
                    <count group_id="O3" value="3713"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.76"/>
                    <measurement group_id="O2" value="78.67"/>
                    <measurement group_id="O3" value="78.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="910"/>
                    <count group_id="O2" value="2665"/>
                    <count group_id="O3" value="3575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.91"/>
                    <measurement group_id="O2" value="78.46"/>
                    <measurement group_id="O3" value="78.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="860"/>
                    <count group_id="O2" value="2565"/>
                    <count group_id="O3" value="3425"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.91"/>
                    <measurement group_id="O2" value="79.42"/>
                    <measurement group_id="O3" value="79.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="824"/>
                    <count group_id="O2" value="2464"/>
                    <count group_id="O3" value="3288"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.61"/>
                    <measurement group_id="O2" value="78.37"/>
                    <measurement group_id="O3" value="78.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="796"/>
                    <count group_id="O2" value="2361"/>
                    <count group_id="O3" value="3157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.15"/>
                    <measurement group_id="O2" value="79.16"/>
                    <measurement group_id="O3" value="79.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="770"/>
                    <count group_id="O2" value="2288"/>
                    <count group_id="O3" value="3058"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00"/>
                    <measurement group_id="O2" value="79.90"/>
                    <measurement group_id="O3" value="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="749"/>
                    <count group_id="O2" value="2219"/>
                    <count group_id="O3" value="2968"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.51"/>
                    <measurement group_id="O2" value="79.81"/>
                    <measurement group_id="O3" value="79.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="730"/>
                    <count group_id="O2" value="2157"/>
                    <count group_id="O3" value="2887"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.78"/>
                    <measurement group_id="O2" value="79.37"/>
                    <measurement group_id="O3" value="79.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="690"/>
                    <count group_id="O2" value="2073"/>
                    <count group_id="O3" value="2763"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.55"/>
                    <measurement group_id="O2" value="81.23"/>
                    <measurement group_id="O3" value="80.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="657"/>
                    <count group_id="O2" value="1907"/>
                    <count group_id="O3" value="2564"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.69"/>
                    <measurement group_id="O2" value="80.49"/>
                    <measurement group_id="O3" value="80.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="616"/>
                    <count group_id="O2" value="1658"/>
                    <count group_id="O3" value="2274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.14"/>
                    <measurement group_id="O2" value="79.55"/>
                    <measurement group_id="O3" value="80.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="581"/>
                    <count group_id="O2" value="1486"/>
                    <count group_id="O3" value="2067"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.31"/>
                    <measurement group_id="O2" value="80.69"/>
                    <measurement group_id="O3" value="80.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="1355"/>
                    <count group_id="O3" value="1845"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.47"/>
                    <measurement group_id="O2" value="80.30"/>
                    <measurement group_id="O3" value="81.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                    <count group_id="O2" value="1208"/>
                    <count group_id="O3" value="1679"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.19"/>
                    <measurement group_id="O2" value="78.97"/>
                    <measurement group_id="O3" value="79.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="441"/>
                    <count group_id="O2" value="1021"/>
                    <count group_id="O3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.73"/>
                    <measurement group_id="O2" value="82.37"/>
                    <measurement group_id="O3" value="81.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="920"/>
                    <count group_id="O3" value="1331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.75"/>
                    <measurement group_id="O2" value="82.39"/>
                    <measurement group_id="O3" value="82.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="1230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.30"/>
                    <measurement group_id="O2" value="82.97"/>
                    <measurement group_id="O3" value="82.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="705"/>
                    <count group_id="O3" value="1087"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.84"/>
                    <measurement group_id="O2" value="81.42"/>
                    <measurement group_id="O3" value="80.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="358"/>
                    <count group_id="O2" value="486"/>
                    <count group_id="O3" value="844"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.68"/>
                    <measurement group_id="O2" value="83.54"/>
                    <measurement group_id="O3" value="83.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="626"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.01"/>
                    <measurement group_id="O2" value="82.58"/>
                    <measurement group_id="O3" value="82.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="309"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.20"/>
                    <measurement group_id="O2" value="78.95"/>
                    <measurement group_id="O3" value="81.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.69"/>
                    <measurement group_id="O2" value="80.22"/>
                    <measurement group_id="O3" value="81.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.52"/>
                    <measurement group_id="O2" value="79.63"/>
                    <measurement group_id="O3" value="82.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.66"/>
                    <measurement group_id="O2" value="81.82"/>
                    <measurement group_id="O3" value="82.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.47"/>
                    <measurement group_id="O2" value="70.73"/>
                    <measurement group_id="O3" value="82.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="241"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.57"/>
                    <measurement group_id="O2" value="74.36"/>
                    <measurement group_id="O3" value="81.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.14"/>
                    <measurement group_id="O2" value="78.57"/>
                    <measurement group_id="O3" value="81.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.47"/>
                    <measurement group_id="O2" value="81.25"/>
                    <measurement group_id="O3" value="78.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.08"/>
                    <measurement group_id="O2" value="90.91"/>
                    <measurement group_id="O3" value="84.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.27"/>
                    <measurement group_id="O2" value="50.00"/>
                    <measurement group_id="O3" value="73.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.33"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="72.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.50"/>
                    <measurement group_id="O2" value="100.00"/>
                    <measurement group_id="O3" value="66.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 111</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                    <measurement group_id="O2" value="100.00"/>
                    <measurement group_id="O3" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20 at Month 114</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                    <measurement group_id="O3" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1114"/>
                    <count group_id="O2" value="3307"/>
                    <count group_id="O3" value="4421"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.67"/>
                    <measurement group_id="O2" value="49.56"/>
                    <measurement group_id="O3" value="49.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1080"/>
                    <count group_id="O2" value="3254"/>
                    <count group_id="O3" value="4334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.19"/>
                    <measurement group_id="O2" value="53.29"/>
                    <measurement group_id="O3" value="52.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1069"/>
                    <count group_id="O2" value="3228"/>
                    <count group_id="O3" value="4297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.45"/>
                    <measurement group_id="O2" value="54.52"/>
                    <measurement group_id="O3" value="53.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1040"/>
                    <count group_id="O2" value="3132"/>
                    <count group_id="O3" value="4172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.79"/>
                    <measurement group_id="O2" value="55.75"/>
                    <measurement group_id="O3" value="55.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1003"/>
                    <count group_id="O2" value="3022"/>
                    <count group_id="O3" value="4025"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.24"/>
                    <measurement group_id="O2" value="55.96"/>
                    <measurement group_id="O3" value="55.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="972"/>
                    <count group_id="O2" value="2891"/>
                    <count group_id="O3" value="3863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.98"/>
                    <measurement group_id="O2" value="56.73"/>
                    <measurement group_id="O3" value="55.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="938"/>
                    <count group_id="O2" value="2775"/>
                    <count group_id="O3" value="3713"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.76"/>
                    <measurement group_id="O2" value="56.61"/>
                    <measurement group_id="O3" value="56.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="910"/>
                    <count group_id="O2" value="2665"/>
                    <count group_id="O3" value="3575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.16"/>
                    <measurement group_id="O2" value="57.30"/>
                    <measurement group_id="O3" value="56.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="860"/>
                    <count group_id="O2" value="2565"/>
                    <count group_id="O3" value="3425"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.77"/>
                    <measurement group_id="O2" value="59.10"/>
                    <measurement group_id="O3" value="58.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="824"/>
                    <count group_id="O2" value="2464"/>
                    <count group_id="O3" value="3288"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.77"/>
                    <measurement group_id="O2" value="57.67"/>
                    <measurement group_id="O3" value="57.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="796"/>
                    <count group_id="O2" value="2361"/>
                    <count group_id="O3" value="3157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.91"/>
                    <measurement group_id="O2" value="58.58"/>
                    <measurement group_id="O3" value="58.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="770"/>
                    <count group_id="O2" value="2288"/>
                    <count group_id="O3" value="3058"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.83"/>
                    <measurement group_id="O2" value="58.65"/>
                    <measurement group_id="O3" value="58.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="749"/>
                    <count group_id="O2" value="2219"/>
                    <count group_id="O3" value="2968"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.68"/>
                    <measurement group_id="O2" value="59.31"/>
                    <measurement group_id="O3" value="58.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="730"/>
                    <count group_id="O2" value="2157"/>
                    <count group_id="O3" value="2887"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.49"/>
                    <measurement group_id="O2" value="58.51"/>
                    <measurement group_id="O3" value="58.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="690"/>
                    <count group_id="O2" value="2073"/>
                    <count group_id="O3" value="2763"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.28"/>
                    <measurement group_id="O2" value="59.29"/>
                    <measurement group_id="O3" value="59.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="657"/>
                    <count group_id="O2" value="1907"/>
                    <count group_id="O3" value="2564"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.60"/>
                    <measurement group_id="O2" value="59.99"/>
                    <measurement group_id="O3" value="59.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="616"/>
                    <count group_id="O2" value="1658"/>
                    <count group_id="O3" value="2274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.42"/>
                    <measurement group_id="O2" value="60.07"/>
                    <measurement group_id="O3" value="59.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="581"/>
                    <count group_id="O2" value="1486"/>
                    <count group_id="O3" value="2067"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.00"/>
                    <measurement group_id="O2" value="57.60"/>
                    <measurement group_id="O3" value="57.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="1355"/>
                    <count group_id="O3" value="1845"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.45"/>
                    <measurement group_id="O2" value="59.19"/>
                    <measurement group_id="O3" value="60.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                    <count group_id="O2" value="1208"/>
                    <count group_id="O3" value="1679"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.60"/>
                    <measurement group_id="O2" value="59.44"/>
                    <measurement group_id="O3" value="59.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="441"/>
                    <count group_id="O2" value="1021"/>
                    <count group_id="O3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.45"/>
                    <measurement group_id="O2" value="61.12"/>
                    <measurement group_id="O3" value="61.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="920"/>
                    <count group_id="O3" value="1331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.53"/>
                    <measurement group_id="O2" value="60.65"/>
                    <measurement group_id="O3" value="61.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="834"/>
                    <count group_id="O3" value="1230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.39"/>
                    <measurement group_id="O2" value="61.99"/>
                    <measurement group_id="O3" value="62.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="705"/>
                    <count group_id="O3" value="1087"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.73"/>
                    <measurement group_id="O2" value="60.85"/>
                    <measurement group_id="O3" value="60.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="358"/>
                    <count group_id="O2" value="486"/>
                    <count group_id="O3" value="844"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.10"/>
                    <measurement group_id="O2" value="61.11"/>
                    <measurement group_id="O3" value="59.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="626"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.54"/>
                    <measurement group_id="O2" value="59.93"/>
                    <measurement group_id="O3" value="61.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="309"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.49"/>
                    <measurement group_id="O2" value="56.14"/>
                    <measurement group_id="O3" value="59.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00"/>
                    <measurement group_id="O2" value="58.24"/>
                    <measurement group_id="O3" value="59.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.99"/>
                    <measurement group_id="O2" value="51.85"/>
                    <measurement group_id="O3" value="62.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.10"/>
                    <measurement group_id="O2" value="54.55"/>
                    <measurement group_id="O3" value="61.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.05"/>
                    <measurement group_id="O2" value="43.90"/>
                    <measurement group_id="O3" value="63.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="241"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.00"/>
                    <measurement group_id="O2" value="46.15"/>
                    <measurement group_id="O3" value="58.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.22"/>
                    <measurement group_id="O2" value="57.14"/>
                    <measurement group_id="O3" value="60.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.11"/>
                    <measurement group_id="O2" value="56.25"/>
                    <measurement group_id="O3" value="60.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.85"/>
                    <measurement group_id="O2" value="54.55"/>
                    <measurement group_id="O3" value="53.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.55"/>
                    <measurement group_id="O2" value="25.00"/>
                    <measurement group_id="O3" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="61.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 111</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="75.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 at Month 114</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                    <measurement group_id="O3" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1114"/>
                    <count group_id="O2" value="3307"/>
                    <count group_id="O3" value="4421"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.66"/>
                    <measurement group_id="O2" value="28.82"/>
                    <measurement group_id="O3" value="28.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1080"/>
                    <count group_id="O2" value="3254"/>
                    <count group_id="O3" value="4334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78"/>
                    <measurement group_id="O2" value="31.53"/>
                    <measurement group_id="O3" value="30.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1069"/>
                    <count group_id="O2" value="3228"/>
                    <count group_id="O3" value="4297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.37"/>
                    <measurement group_id="O2" value="33.09"/>
                    <measurement group_id="O3" value="32.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1040"/>
                    <count group_id="O2" value="3132"/>
                    <count group_id="O3" value="4172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.06"/>
                    <measurement group_id="O2" value="33.75"/>
                    <measurement group_id="O3" value="33.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1003"/>
                    <count group_id="O2" value="3022"/>
                    <count group_id="O3" value="4025"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.80"/>
                    <measurement group_id="O2" value="34.91"/>
                    <measurement group_id="O3" value="34.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="972"/>
                    <count group_id="O2" value="2891"/>
                    <count group_id="O3" value="3863"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.38"/>
                    <measurement group_id="O2" value="35.84"/>
                    <measurement group_id="O3" value="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="938"/>
                    <count group_id="O2" value="2775"/>
                    <count group_id="O3" value="3713"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.94"/>
                    <measurement group_id="O2" value="36.54"/>
                    <measurement group_id="O3" value="35.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="910"/>
                    <count group_id="O2" value="2665"/>
                    <count group_id="O3" value="3575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.82"/>
                    <measurement group_id="O2" value="36.40"/>
                    <measurement group_id="O3" value="36.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="860"/>
                    <count group_id="O2" value="2565"/>
                    <count group_id="O3" value="3425"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.49"/>
                    <measurement group_id="O2" value="37.66"/>
                    <measurement group_id="O3" value="36.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="824"/>
                    <count group_id="O2" value="2464"/>
                    <count group_id="O3" value="3288"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.44"/>
                    <measurement group_id="O2" value="38.15"/>
                    <measurement group_id="O3" value="37.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="796"/>
                    <count group_id="O2" value="2361"/>
                    <count group_id="O3" value="3157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.06"/>
                    <measurement group_id="O2" value="38.33"/>
                    <measurement group_id="O3" value="37.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="770"/>
                    <count group_id="O2" value="2288"/>
                    <count group_id="O3" value="3058"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.27"/>
                    <measurement group_id="O2" value="38.99"/>
                    <measurement group_id="O3" value="38.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="749"/>
                    <count group_id="O2" value="2219"/>
                    <count group_id="O3" value="2968"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.64"/>
                    <measurement group_id="O2" value="38.26"/>
                    <measurement group_id="O3" value="37.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="730"/>
                    <count group_id="O2" value="2157"/>
                    <count group_id="O3" value="2887"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.71"/>
                    <measurement group_id="O2" value="37.41"/>
                    <measurement group_id="O3" value="37.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="690"/>
                    <count group_id="O2" value="2073"/>
                    <count group_id="O3" value="2763"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.41"/>
                    <measurement group_id="O2" value="38.88"/>
                    <measurement group_id="O3" value="38.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="657"/>
                    <count group_id="O2" value="1907"/>
                    <count group_id="O3" value="2564"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.77"/>
                    <measurement group_id="O2" value="38.91"/>
                    <measurement group_id="O3" value="38.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="616"/>
                    <count group_id="O2" value="1658"/>
                    <count group_id="O3" value="2274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.69"/>
                    <measurement group_id="O2" value="38.18"/>
                    <measurement group_id="O3" value="37.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="581"/>
                    <count group_id="O2" value="1486"/>
                    <count group_id="O3" value="2067"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.97"/>
                    <measurement group_id="O2" value="37.01"/>
                    <measurement group_id="O3" value="36.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="1355"/>
                    <count group_id="O3" value="1845"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.59"/>
                    <measurement group_id="O2" value="37.34"/>
                    <measurement group_id="O3" value="37.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                    <count group_id="O2" value="1208"/>
                    <count group_id="O3" value="1679"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.73"/>
                    <measurement group_id="O2" value="39.32"/>
                    <measurement group_id="O3" value="38.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="441"/>
                    <count group_id="O2" value="1021"/>
                    <count group_id="O3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.78"/>
                    <measurement group_id="O2" value="39.47"/>
                    <measurement group_id="O3" value="39.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="920"/>
                    <count group_id="O3" value="1331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.96"/>
                    <measurement group_id="O2" value="38.91"/>
                    <measurement group_id="O3" value="38.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="834"/>
                    <count group_id="O3" value="1230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.64"/>
                    <measurement group_id="O2" value="39.33"/>
                    <measurement group_id="O3" value="39.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="705"/>
                    <count group_id="O3" value="1087"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.22"/>
                    <measurement group_id="O2" value="40.14"/>
                    <measurement group_id="O3" value="39.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="358"/>
                    <count group_id="O2" value="486"/>
                    <count group_id="O3" value="844"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.55"/>
                    <measurement group_id="O2" value="41.56"/>
                    <measurement group_id="O3" value="40.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="626"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.12"/>
                    <measurement group_id="O2" value="36.59"/>
                    <measurement group_id="O3" value="38.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="309"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.13"/>
                    <measurement group_id="O2" value="36.84"/>
                    <measurement group_id="O3" value="38.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.37"/>
                    <measurement group_id="O2" value="32.97"/>
                    <measurement group_id="O3" value="40.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.26"/>
                    <measurement group_id="O2" value="35.19"/>
                    <measurement group_id="O3" value="40.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.07"/>
                    <measurement group_id="O2" value="31.82"/>
                    <measurement group_id="O3" value="40.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.80"/>
                    <measurement group_id="O2" value="21.95"/>
                    <measurement group_id="O3" value="40.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="241"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.17"/>
                    <measurement group_id="O2" value="25.64"/>
                    <measurement group_id="O3" value="36.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.84"/>
                    <measurement group_id="O2" value="39.29"/>
                    <measurement group_id="O3" value="41.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.75"/>
                    <measurement group_id="O2" value="31.25"/>
                    <measurement group_id="O3" value="42.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00"/>
                    <measurement group_id="O2" value="18.18"/>
                    <measurement group_id="O3" value="36.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.91"/>
                    <measurement group_id="O2" value="25.00"/>
                    <measurement group_id="O3" value="38.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.67"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 111</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="75.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 at Month 114</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                    <measurement group_id="O3" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under American College of Rheumatology (ACR) n Curve</title>
        <description>No data were collected for this endpoint because it was removed from the protocol in a previous amendment.</description>
        <time_frame>Not applicable as no data were collected for this endpoint.</time_frame>
        <population>No data were collected for this endpoint as it was removed from the protocol in a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligram (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under American College of Rheumatology (ACR) n Curve</title>
          <description>No data were collected for this endpoint because it was removed from the protocol in a previous amendment.</description>
          <population>No data were collected for this endpoint as it was removed from the protocol in a protocol amendment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score (DAS)28 (C-reactive Protein [CRP]) and DAS28 (Erythrocyte Sedimentation Rate [ESR])</title>
        <description>Descriptive statistics for DAS28-3 (CRP) and DAS28-4 (ESR). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula.
The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of &gt;5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of &lt;2.6 indicates disease remission.</description>
        <time_frame>Every visit until study completion</time_frame>
        <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligram (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score (DAS)28 (C-reactive Protein [CRP]) and DAS28 (Erythrocyte Sedimentation Rate [ESR])</title>
          <description>Descriptive statistics for DAS28-3 (CRP) and DAS28-4 (ESR). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula.
The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of &gt;5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of &lt;2.6 indicates disease remission.</description>
          <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
          <units>Score calculated from formula</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-4 (ESR) Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1002"/>
                    <count group_id="O2" value="3296"/>
                    <count group_id="O3" value="4298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" spread="1.02"/>
                    <measurement group_id="O2" value="6.39" spread="1.04"/>
                    <measurement group_id="O3" value="6.36" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1036"/>
                    <count group_id="O2" value="3254"/>
                    <count group_id="O3" value="4290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.81" spread="1.32"/>
                    <measurement group_id="O2" value="3.78" spread="1.36"/>
                    <measurement group_id="O3" value="3.79" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1026"/>
                    <count group_id="O2" value="3222"/>
                    <count group_id="O3" value="4248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="1.27"/>
                    <measurement group_id="O2" value="3.66" spread="1.32"/>
                    <measurement group_id="O3" value="3.68" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1033"/>
                    <count group_id="O2" value="3203"/>
                    <count group_id="O3" value="4236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="1.32"/>
                    <measurement group_id="O2" value="3.61" spread="1.30"/>
                    <measurement group_id="O3" value="3.65" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1015"/>
                    <count group_id="O2" value="3110"/>
                    <count group_id="O3" value="4125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="1.33"/>
                    <measurement group_id="O2" value="3.61" spread="1.30"/>
                    <measurement group_id="O3" value="3.62" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="992"/>
                    <count group_id="O2" value="3003"/>
                    <count group_id="O3" value="3995"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="1.31"/>
                    <measurement group_id="O2" value="3.58" spread="1.32"/>
                    <measurement group_id="O3" value="3.59" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="967"/>
                    <count group_id="O2" value="2862"/>
                    <count group_id="O3" value="3829"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="1.26"/>
                    <measurement group_id="O2" value="3.56" spread="1.30"/>
                    <measurement group_id="O3" value="3.57" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="922"/>
                    <count group_id="O2" value="2759"/>
                    <count group_id="O3" value="3681"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="1.26"/>
                    <measurement group_id="O2" value="3.53" spread="1.30"/>
                    <measurement group_id="O3" value="3.53" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="899"/>
                    <count group_id="O2" value="2655"/>
                    <count group_id="O3" value="3554"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="1.26"/>
                    <measurement group_id="O2" value="3.50" spread="1.28"/>
                    <measurement group_id="O3" value="3.52" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="850"/>
                    <count group_id="O2" value="2547"/>
                    <count group_id="O3" value="3397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="1.25"/>
                    <measurement group_id="O2" value="3.45" spread="1.27"/>
                    <measurement group_id="O3" value="3.48" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="818"/>
                    <count group_id="O2" value="2441"/>
                    <count group_id="O3" value="3259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="1.21"/>
                    <measurement group_id="O2" value="3.46" spread="1.26"/>
                    <measurement group_id="O3" value="3.48" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="787"/>
                    <count group_id="O2" value="2343"/>
                    <count group_id="O3" value="3130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" spread="1.20"/>
                    <measurement group_id="O2" value="3.44" spread="1.25"/>
                    <measurement group_id="O3" value="3.46" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="764"/>
                    <count group_id="O2" value="2257"/>
                    <count group_id="O3" value="3021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="1.23"/>
                    <measurement group_id="O2" value="3.43" spread="1.25"/>
                    <measurement group_id="O3" value="3.46" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="746"/>
                    <count group_id="O2" value="2199"/>
                    <count group_id="O3" value="2945"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.22"/>
                    <measurement group_id="O2" value="3.42" spread="1.27"/>
                    <measurement group_id="O3" value="3.45" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="720"/>
                    <count group_id="O2" value="2141"/>
                    <count group_id="O3" value="2861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.23"/>
                    <measurement group_id="O2" value="3.42" spread="1.27"/>
                    <measurement group_id="O3" value="3.44" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="679"/>
                    <count group_id="O2" value="2056"/>
                    <count group_id="O3" value="2735"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="1.27"/>
                    <measurement group_id="O2" value="3.39" spread="1.24"/>
                    <measurement group_id="O3" value="3.43" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="642"/>
                    <count group_id="O2" value="1890"/>
                    <count group_id="O3" value="2532"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="1.26"/>
                    <measurement group_id="O2" value="3.40" spread="1.26"/>
                    <measurement group_id="O3" value="3.43" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="1641"/>
                    <count group_id="O3" value="2250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="1.20"/>
                    <measurement group_id="O2" value="3.37" spread="1.21"/>
                    <measurement group_id="O3" value="3.39" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="570"/>
                    <count group_id="O2" value="1471"/>
                    <count group_id="O3" value="2041"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="1.16"/>
                    <measurement group_id="O2" value="3.36" spread="1.21"/>
                    <measurement group_id="O3" value="3.39" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="481"/>
                    <count group_id="O2" value="1344"/>
                    <count group_id="O3" value="1825"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="1.20"/>
                    <measurement group_id="O2" value="3.39" spread="1.24"/>
                    <measurement group_id="O3" value="3.40" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="467"/>
                    <count group_id="O2" value="1194"/>
                    <count group_id="O3" value="1661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="1.23"/>
                    <measurement group_id="O2" value="3.38" spread="1.25"/>
                    <measurement group_id="O3" value="3.42" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="1006"/>
                    <count group_id="O3" value="1444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="1.19"/>
                    <measurement group_id="O2" value="3.36" spread="1.21"/>
                    <measurement group_id="O3" value="3.40" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="908"/>
                    <count group_id="O3" value="1316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.27"/>
                    <measurement group_id="O2" value="3.34" spread="1.20"/>
                    <measurement group_id="O3" value="3.39" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="825"/>
                    <count group_id="O3" value="1213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.15"/>
                    <measurement group_id="O2" value="3.30" spread="1.16"/>
                    <measurement group_id="O3" value="3.37" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="700"/>
                    <count group_id="O3" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="1.12"/>
                    <measurement group_id="O2" value="3.34" spread="1.17"/>
                    <measurement group_id="O3" value="3.42" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="355"/>
                    <count group_id="O2" value="483"/>
                    <count group_id="O3" value="838"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.18"/>
                    <measurement group_id="O2" value="3.35" spread="1.20"/>
                    <measurement group_id="O3" value="3.41" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="284"/>
                    <count group_id="O3" value="622"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="1.20"/>
                    <measurement group_id="O2" value="3.42" spread="1.19"/>
                    <measurement group_id="O3" value="3.44" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="1.11"/>
                    <measurement group_id="O2" value="3.41" spread="1.14"/>
                    <measurement group_id="O3" value="3.43" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="382"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="1.14"/>
                    <measurement group_id="O2" value="3.32" spread="1.20"/>
                    <measurement group_id="O3" value="3.41" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="1.11"/>
                    <measurement group_id="O2" value="3.56" spread="1.24"/>
                    <measurement group_id="O3" value="3.42" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread="1.13"/>
                    <measurement group_id="O2" value="3.42" spread="1.37"/>
                    <measurement group_id="O3" value="3.34" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="263"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="1.13"/>
                    <measurement group_id="O2" value="3.19" spread="1.15"/>
                    <measurement group_id="O3" value="3.31" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="1.14"/>
                    <measurement group_id="O2" value="3.28" spread="1.10"/>
                    <measurement group_id="O3" value="3.33" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="1.14"/>
                    <measurement group_id="O2" value="3.23" spread="1.12"/>
                    <measurement group_id="O3" value="3.32" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="1.12"/>
                    <measurement group_id="O2" value="3.48" spread="1.06"/>
                    <measurement group_id="O3" value="3.32" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="1.07"/>
                    <measurement group_id="O2" value="3.04" spread="1.24"/>
                    <measurement group_id="O3" value="3.23" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="1.47"/>
                    <measurement group_id="O2" value="3.10" spread="1.76"/>
                    <measurement group_id="O3" value="3.30" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="1.52"/>
                    <measurement group_id="O2" value="2.65" spread="0.97"/>
                    <measurement group_id="O3" value="3.46" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="1.76"/>
                    <measurement group_id="O2" value="4.65" spread="0"/>
                    <measurement group_id="O3" value="3.51" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 111</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.69"/>
                    <measurement group_id="O2" value="3.59" spread="0"/>
                    <measurement group_id="O3" value="2.42" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) Month 114</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0"/>
                    <measurement group_id="O3" value="1.28" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1112"/>
                    <count group_id="O2" value="3340"/>
                    <count group_id="O3" value="4452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31" spread="0.95"/>
                    <measurement group_id="O2" value="5.34" spread="0.98"/>
                    <measurement group_id="O3" value="5.33" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1096"/>
                    <count group_id="O2" value="3234"/>
                    <count group_id="O3" value="4330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="1.19"/>
                    <measurement group_id="O2" value="2.96" spread="1.22"/>
                    <measurement group_id="O3" value="2.99" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1070"/>
                    <count group_id="O2" value="3180"/>
                    <count group_id="O3" value="4250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" spread="1.15"/>
                    <measurement group_id="O2" value="2.87" spread="1.17"/>
                    <measurement group_id="O3" value="2.90" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1057"/>
                    <count group_id="O2" value="3190"/>
                    <count group_id="O3" value="4247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="1.15"/>
                    <measurement group_id="O2" value="2.81" spread="1.15"/>
                    <measurement group_id="O3" value="2.85" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1026"/>
                    <count group_id="O2" value="3106"/>
                    <count group_id="O3" value="4132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="1.16"/>
                    <measurement group_id="O2" value="2.79" spread="1.15"/>
                    <measurement group_id="O3" value="2.81" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="993"/>
                    <count group_id="O2" value="3008"/>
                    <count group_id="O3" value="4001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="1.12"/>
                    <measurement group_id="O2" value="2.74" spread="1.16"/>
                    <measurement group_id="O3" value="2.76" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="962"/>
                    <count group_id="O2" value="2874"/>
                    <count group_id="O3" value="3836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="1.11"/>
                    <measurement group_id="O2" value="2.72" spread="1.13"/>
                    <measurement group_id="O3" value="2.74" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="923"/>
                    <count group_id="O2" value="2761"/>
                    <count group_id="O3" value="3684"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="1.10"/>
                    <measurement group_id="O2" value="2.69" spread="1.13"/>
                    <measurement group_id="O3" value="2.70" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="899"/>
                    <count group_id="O2" value="2654"/>
                    <count group_id="O3" value="3553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="1.11"/>
                    <measurement group_id="O2" value="2.66" spread="1.11"/>
                    <measurement group_id="O3" value="2.68" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="856"/>
                    <count group_id="O2" value="2556"/>
                    <count group_id="O3" value="3412"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="1.12"/>
                    <measurement group_id="O2" value="2.62" spread="1.09"/>
                    <measurement group_id="O3" value="2.65" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="813"/>
                    <count group_id="O2" value="2456"/>
                    <count group_id="O3" value="3269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="1.07"/>
                    <measurement group_id="O2" value="2.63" spread="1.11"/>
                    <measurement group_id="O3" value="2.64" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="793"/>
                    <count group_id="O2" value="2345"/>
                    <count group_id="O3" value="3138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="1.06"/>
                    <measurement group_id="O2" value="2.60" spread="1.09"/>
                    <measurement group_id="O3" value="2.62" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="766"/>
                    <count group_id="O2" value="2271"/>
                    <count group_id="O3" value="3037"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="1.07"/>
                    <measurement group_id="O2" value="2.59" spread="1.09"/>
                    <measurement group_id="O3" value="2.60" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="745"/>
                    <count group_id="O2" value="2209"/>
                    <count group_id="O3" value="2954"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="1.06"/>
                    <measurement group_id="O2" value="2.58" spread="1.10"/>
                    <measurement group_id="O3" value="2.60" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="724"/>
                    <count group_id="O2" value="2142"/>
                    <count group_id="O3" value="2866"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="1.07"/>
                    <measurement group_id="O2" value="2.59" spread="1.08"/>
                    <measurement group_id="O3" value="2.60" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="686"/>
                    <count group_id="O2" value="2057"/>
                    <count group_id="O3" value="2743"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="1.10"/>
                    <measurement group_id="O2" value="2.57" spread="1.07"/>
                    <measurement group_id="O3" value="2.59" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="653"/>
                    <count group_id="O2" value="1893"/>
                    <count group_id="O3" value="2546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="1.09"/>
                    <measurement group_id="O2" value="2.57" spread="1.09"/>
                    <measurement group_id="O3" value="2.59" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="611"/>
                    <count group_id="O2" value="1644"/>
                    <count group_id="O3" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="1.04"/>
                    <measurement group_id="O2" value="2.53" spread="1.03"/>
                    <measurement group_id="O3" value="2.54" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="579"/>
                    <count group_id="O2" value="1469"/>
                    <count group_id="O3" value="2048"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="1.03"/>
                    <measurement group_id="O2" value="2.54" spread="1.05"/>
                    <measurement group_id="O3" value="2.56" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="487"/>
                    <count group_id="O2" value="1348"/>
                    <count group_id="O3" value="1835"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="0.99"/>
                    <measurement group_id="O2" value="2.57" spread="1.07"/>
                    <measurement group_id="O3" value="2.57" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="1198"/>
                    <count group_id="O3" value="1666"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="1.07"/>
                    <measurement group_id="O2" value="2.56" spread="1.05"/>
                    <measurement group_id="O3" value="2.59" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="1011"/>
                    <count group_id="O3" value="1450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="1.03"/>
                    <measurement group_id="O2" value="2.54" spread="1.04"/>
                    <measurement group_id="O3" value="2.56" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="913"/>
                    <count group_id="O3" value="1320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="1.09"/>
                    <measurement group_id="O2" value="2.53" spread="1.03"/>
                    <measurement group_id="O3" value="2.57" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="824"/>
                    <count group_id="O3" value="1214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="1.01"/>
                    <measurement group_id="O2" value="2.51" spread="0.98"/>
                    <measurement group_id="O3" value="2.56" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="702"/>
                    <count group_id="O3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="1.02"/>
                    <measurement group_id="O2" value="2.53" spread="1.01"/>
                    <measurement group_id="O3" value="2.59" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="355"/>
                    <count group_id="O2" value="483"/>
                    <count group_id="O3" value="838"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="1.06"/>
                    <measurement group_id="O2" value="2.55" spread="1.00"/>
                    <measurement group_id="O3" value="2.60" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="337"/>
                    <count group_id="O2" value="285"/>
                    <count group_id="O3" value="622"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="1.04"/>
                    <measurement group_id="O2" value="2.64" spread="1.03"/>
                    <measurement group_id="O3" value="2.64" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="1.05"/>
                    <measurement group_id="O2" value="2.59" spread="1.02"/>
                    <measurement group_id="O3" value="2.61" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="1.02"/>
                    <measurement group_id="O2" value="2.68" spread="1.01"/>
                    <measurement group_id="O3" value="2.61" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="0.96"/>
                    <measurement group_id="O2" value="2.82" spread="1.13"/>
                    <measurement group_id="O3" value="2.59" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.94"/>
                    <measurement group_id="O2" value="2.84" spread="1.20"/>
                    <measurement group_id="O3" value="2.54" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="0.97"/>
                    <measurement group_id="O2" value="2.56" spread="0.91"/>
                    <measurement group_id="O3" value="2.52" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="1.00"/>
                    <measurement group_id="O2" value="2.58" spread="0.95"/>
                    <measurement group_id="O3" value="2.55" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="1.00"/>
                    <measurement group_id="O2" value="2.59" spread="0.85"/>
                    <measurement group_id="O3" value="2.59" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="0.93"/>
                    <measurement group_id="O2" value="2.68" spread="0.80"/>
                    <measurement group_id="O3" value="2.60" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="0.89"/>
                    <measurement group_id="O2" value="2.49" spread="1.12"/>
                    <measurement group_id="O3" value="2.57" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.78"/>
                    <measurement group_id="O2" value="2.29" spread="1.01"/>
                    <measurement group_id="O3" value="2.59" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="1.23"/>
                    <measurement group_id="O2" value="1.76" spread="0.34"/>
                    <measurement group_id="O3" value="3.09" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="1.59"/>
                    <measurement group_id="O2" value="3.70" spread="0"/>
                    <measurement group_id="O3" value="3.49" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 111</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.50"/>
                    <measurement group_id="O2" value="2.49" spread="0"/>
                    <measurement group_id="O3" value="1.98" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) Month 114</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0"/>
                    <measurement group_id="O3" value="2.67" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number (%) of Participants With DAS28-4 (ESR) and DAS28-3 (CRP) &lt;2.6 and ≤3.2</title>
        <description>Percent participants with DAS28-4 (ESR) &lt;2.6 and ≤3.2 and percent participants with DAS28-3 (CRP) &lt;2.6 and ≤3.2. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula.
The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of &gt;5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of &lt;2.6 indicates disease remission.</description>
        <time_frame>Every visit until study completion</time_frame>
        <population>Full Analysis Set - No Imputation. The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>Number (%) of Participants With DAS28-4 (ESR) and DAS28-3 (CRP) &lt;2.6 and ≤3.2</title>
          <description>Percent participants with DAS28-4 (ESR) &lt;2.6 and ≤3.2 and percent participants with DAS28-3 (CRP) &lt;2.6 and ≤3.2. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula.
The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of &gt;5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of &lt;2.6 indicates disease remission.</description>
          <population>Full Analysis Set - No Imputation. The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1002"/>
                    <count group_id="O2" value="3296"/>
                    <count group_id="O3" value="4298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1036"/>
                    <count group_id="O2" value="3254"/>
                    <count group_id="O3" value="4290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1026"/>
                    <count group_id="O2" value="3222"/>
                    <count group_id="O3" value="4248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="22.5"/>
                    <measurement group_id="O3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1033"/>
                    <count group_id="O2" value="3203"/>
                    <count group_id="O3" value="4236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1015"/>
                    <count group_id="O2" value="3110"/>
                    <count group_id="O3" value="4125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="23.4"/>
                    <measurement group_id="O3" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="992"/>
                    <count group_id="O2" value="3003"/>
                    <count group_id="O3" value="3995"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="25.1"/>
                    <measurement group_id="O3" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="967"/>
                    <count group_id="O2" value="2862"/>
                    <count group_id="O3" value="3829"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="922"/>
                    <count group_id="O2" value="2759"/>
                    <count group_id="O3" value="3681"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="899"/>
                    <count group_id="O2" value="2655"/>
                    <count group_id="O3" value="3554"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="26.9"/>
                    <measurement group_id="O3" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="850"/>
                    <count group_id="O2" value="2547"/>
                    <count group_id="O3" value="3397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="27.1"/>
                    <measurement group_id="O3" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="818"/>
                    <count group_id="O2" value="2441"/>
                    <count group_id="O3" value="3259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="787"/>
                    <count group_id="O2" value="2343"/>
                    <count group_id="O3" value="3130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="764"/>
                    <count group_id="O2" value="2257"/>
                    <count group_id="O3" value="3021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="27.7"/>
                    <measurement group_id="O3" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="746"/>
                    <count group_id="O2" value="2199"/>
                    <count group_id="O3" value="2945"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="28.3"/>
                    <measurement group_id="O3" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="720"/>
                    <count group_id="O2" value="2141"/>
                    <count group_id="O3" value="2861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="679"/>
                    <count group_id="O2" value="2056"/>
                    <count group_id="O3" value="2735"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="28.4"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="642"/>
                    <count group_id="O2" value="1890"/>
                    <count group_id="O3" value="2532"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="1641"/>
                    <count group_id="O3" value="2250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="27.5"/>
                    <measurement group_id="O3" value="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="570"/>
                    <count group_id="O2" value="1471"/>
                    <count group_id="O3" value="2041"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="481"/>
                    <count group_id="O2" value="1344"/>
                    <count group_id="O3" value="1825"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="467"/>
                    <count group_id="O2" value="1194"/>
                    <count group_id="O3" value="1661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="28.3"/>
                    <measurement group_id="O3" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="1006"/>
                    <count group_id="O3" value="1444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="908"/>
                    <count group_id="O3" value="1316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="825"/>
                    <count group_id="O3" value="1213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="29.5"/>
                    <measurement group_id="O3" value="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="700"/>
                    <count group_id="O3" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="26.9"/>
                    <measurement group_id="O3" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="355"/>
                    <count group_id="O2" value="483"/>
                    <count group_id="O3" value="838"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="26.3"/>
                    <measurement group_id="O3" value="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="284"/>
                    <count group_id="O3" value="622"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="382"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7"/>
                    <measurement group_id="O2" value="33.0"/>
                    <measurement group_id="O3" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="22.2"/>
                    <measurement group_id="O3" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="263"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2"/>
                    <measurement group_id="O2" value="31.7"/>
                    <measurement group_id="O3" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;2.6 Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1002"/>
                    <count group_id="O2" value="3296"/>
                    <count group_id="O3" value="4298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1036"/>
                    <count group_id="O2" value="3254"/>
                    <count group_id="O3" value="4290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="37.6"/>
                    <measurement group_id="O3" value="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1026"/>
                    <count group_id="O2" value="3222"/>
                    <count group_id="O3" value="4248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="40.5"/>
                    <measurement group_id="O3" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1033"/>
                    <count group_id="O2" value="3203"/>
                    <count group_id="O3" value="4236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="41.6"/>
                    <measurement group_id="O3" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1015"/>
                    <count group_id="O2" value="3110"/>
                    <count group_id="O3" value="4125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8"/>
                    <measurement group_id="O2" value="42.5"/>
                    <measurement group_id="O3" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="992"/>
                    <count group_id="O2" value="3003"/>
                    <count group_id="O3" value="3995"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3"/>
                    <measurement group_id="O2" value="43.8"/>
                    <measurement group_id="O3" value="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="967"/>
                    <count group_id="O2" value="2862"/>
                    <count group_id="O3" value="3829"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="42.5"/>
                    <measurement group_id="O3" value="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="899"/>
                    <count group_id="O2" value="2655"/>
                    <count group_id="O3" value="3554"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="850"/>
                    <count group_id="O2" value="2547"/>
                    <count group_id="O3" value="3397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="818"/>
                    <count group_id="O2" value="2441"/>
                    <count group_id="O3" value="3259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                    <measurement group_id="O2" value="46.5"/>
                    <measurement group_id="O3" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="787"/>
                    <count group_id="O2" value="2343"/>
                    <count group_id="O3" value="3130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="764"/>
                    <count group_id="O2" value="2257"/>
                    <count group_id="O3" value="3021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="746"/>
                    <count group_id="O2" value="2199"/>
                    <count group_id="O3" value="2945"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8"/>
                    <measurement group_id="O2" value="47.5"/>
                    <measurement group_id="O3" value="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="720"/>
                    <count group_id="O2" value="2141"/>
                    <count group_id="O3" value="2861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6"/>
                    <measurement group_id="O2" value="48.4"/>
                    <measurement group_id="O3" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="679"/>
                    <count group_id="O2" value="2056"/>
                    <count group_id="O3" value="2735"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6"/>
                    <measurement group_id="O2" value="48.3"/>
                    <measurement group_id="O3" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="642"/>
                    <count group_id="O2" value="1890"/>
                    <count group_id="O3" value="2532"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                    <measurement group_id="O2" value="49.2"/>
                    <measurement group_id="O3" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="1641"/>
                    <count group_id="O3" value="2250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                    <measurement group_id="O2" value="48.4"/>
                    <measurement group_id="O3" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="570"/>
                    <count group_id="O2" value="1471"/>
                    <count group_id="O3" value="2041"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1"/>
                    <measurement group_id="O2" value="49.4"/>
                    <measurement group_id="O3" value="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="481"/>
                    <count group_id="O2" value="1344"/>
                    <count group_id="O3" value="1825"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                    <measurement group_id="O2" value="49.0"/>
                    <measurement group_id="O3" value="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="467"/>
                    <count group_id="O2" value="1194"/>
                    <count group_id="O3" value="1661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7"/>
                    <measurement group_id="O2" value="49.4"/>
                    <measurement group_id="O3" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="1006"/>
                    <count group_id="O3" value="1444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="50.3"/>
                    <measurement group_id="O3" value="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="908"/>
                    <count group_id="O3" value="1316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="49.9"/>
                    <measurement group_id="O3" value="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="825"/>
                    <count group_id="O3" value="1213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="49.9"/>
                    <measurement group_id="O3" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="700"/>
                    <count group_id="O3" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8"/>
                    <measurement group_id="O2" value="49.7"/>
                    <measurement group_id="O3" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="355"/>
                    <count group_id="O2" value="483"/>
                    <count group_id="O3" value="838"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6"/>
                    <measurement group_id="O2" value="50.3"/>
                    <measurement group_id="O3" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="284"/>
                    <count group_id="O3" value="622"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="48.2"/>
                    <measurement group_id="O3" value="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1"/>
                    <measurement group_id="O2" value="48.5"/>
                    <measurement group_id="O3" value="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="382"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="45.1"/>
                    <measurement group_id="O3" value="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3"/>
                    <measurement group_id="O2" value="48.1"/>
                    <measurement group_id="O3" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                    <measurement group_id="O2" value="45.5"/>
                    <measurement group_id="O3" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="263"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9"/>
                    <measurement group_id="O2" value="46.3"/>
                    <measurement group_id="O3" value="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                    <measurement group_id="O2" value="43.8"/>
                    <measurement group_id="O3" value="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (ESR) &lt;/=3.2 Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1112"/>
                    <count group_id="O2" value="3340"/>
                    <count group_id="O3" value="4452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1096"/>
                    <count group_id="O2" value="3234"/>
                    <count group_id="O3" value="4330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="43.0"/>
                    <measurement group_id="O3" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1070"/>
                    <count group_id="O2" value="3180"/>
                    <count group_id="O3" value="4250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1057"/>
                    <count group_id="O2" value="3190"/>
                    <count group_id="O3" value="4247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3"/>
                    <measurement group_id="O2" value="47.5"/>
                    <measurement group_id="O3" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1026"/>
                    <count group_id="O2" value="3106"/>
                    <count group_id="O3" value="4132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="49.0"/>
                    <measurement group_id="O3" value="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="993"/>
                    <count group_id="O2" value="3008"/>
                    <count group_id="O3" value="4001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="50.7"/>
                    <measurement group_id="O3" value="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="962"/>
                    <count group_id="O2" value="2874"/>
                    <count group_id="O3" value="3836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="51.8"/>
                    <measurement group_id="O3" value="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="923"/>
                    <count group_id="O2" value="2761"/>
                    <count group_id="O3" value="3684"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6"/>
                    <measurement group_id="O2" value="52.3"/>
                    <measurement group_id="O3" value="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="899"/>
                    <count group_id="O2" value="2654"/>
                    <count group_id="O3" value="3553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                    <measurement group_id="O2" value="54.1"/>
                    <measurement group_id="O3" value="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="856"/>
                    <count group_id="O2" value="2556"/>
                    <count group_id="O3" value="3412"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="55.5"/>
                    <measurement group_id="O3" value="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="813"/>
                    <count group_id="O2" value="2456"/>
                    <count group_id="O3" value="3269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="55.3"/>
                    <measurement group_id="O3" value="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="793"/>
                    <count group_id="O2" value="2345"/>
                    <count group_id="O3" value="3138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="766"/>
                    <count group_id="O2" value="2271"/>
                    <count group_id="O3" value="3037"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="56.8"/>
                    <measurement group_id="O3" value="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="745"/>
                    <count group_id="O2" value="2209"/>
                    <count group_id="O3" value="2954"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1"/>
                    <measurement group_id="O2" value="56.0"/>
                    <measurement group_id="O3" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="724"/>
                    <count group_id="O2" value="2142"/>
                    <count group_id="O3" value="2866"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9"/>
                    <measurement group_id="O2" value="55.6"/>
                    <measurement group_id="O3" value="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="686"/>
                    <count group_id="O2" value="2057"/>
                    <count group_id="O3" value="2743"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2"/>
                    <measurement group_id="O2" value="56.9"/>
                    <measurement group_id="O3" value="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="653"/>
                    <count group_id="O2" value="1893"/>
                    <count group_id="O3" value="2546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2"/>
                    <measurement group_id="O2" value="56.8"/>
                    <measurement group_id="O3" value="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="611"/>
                    <count group_id="O2" value="1644"/>
                    <count group_id="O3" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                    <measurement group_id="O2" value="58.6"/>
                    <measurement group_id="O3" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="579"/>
                    <count group_id="O2" value="1469"/>
                    <count group_id="O3" value="2048"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="59.3"/>
                    <measurement group_id="O3" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="487"/>
                    <count group_id="O2" value="1348"/>
                    <count group_id="O3" value="1835"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                    <measurement group_id="O2" value="57.3"/>
                    <measurement group_id="O3" value="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="1198"/>
                    <count group_id="O3" value="1666"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6"/>
                    <measurement group_id="O2" value="57.8"/>
                    <measurement group_id="O3" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="1011"/>
                    <count group_id="O3" value="1450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="57.7"/>
                    <measurement group_id="O3" value="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="913"/>
                    <count group_id="O3" value="1320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                    <measurement group_id="O2" value="57.9"/>
                    <measurement group_id="O3" value="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="824"/>
                    <count group_id="O3" value="1214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="58.1"/>
                    <measurement group_id="O3" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="702"/>
                    <count group_id="O3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="59.3"/>
                    <measurement group_id="O3" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="355"/>
                    <count group_id="O2" value="483"/>
                    <count group_id="O3" value="838"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5"/>
                    <measurement group_id="O2" value="57.8"/>
                    <measurement group_id="O3" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="337"/>
                    <count group_id="O2" value="285"/>
                    <count group_id="O3" value="622"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="55.4"/>
                    <measurement group_id="O3" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9"/>
                    <measurement group_id="O2" value="53.5"/>
                    <measurement group_id="O3" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2"/>
                    <measurement group_id="O2" value="51.6"/>
                    <measurement group_id="O3" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2"/>
                    <measurement group_id="O2" value="48.8"/>
                    <measurement group_id="O3" value="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                    <measurement group_id="O2" value="53.6"/>
                    <measurement group_id="O3" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="63.6"/>
                    <measurement group_id="O3" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;2.6 Month 111</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1096"/>
                    <count group_id="O2" value="3234"/>
                    <count group_id="O3" value="4330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1070"/>
                    <count group_id="O2" value="3180"/>
                    <count group_id="O3" value="4250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="64.5"/>
                    <measurement group_id="O3" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1057"/>
                    <count group_id="O2" value="3190"/>
                    <count group_id="O3" value="4247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6"/>
                    <measurement group_id="O2" value="66.3"/>
                    <measurement group_id="O3" value="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1026"/>
                    <count group_id="O2" value="3106"/>
                    <count group_id="O3" value="4132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4"/>
                    <measurement group_id="O2" value="67.1"/>
                    <measurement group_id="O3" value="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="993"/>
                    <count group_id="O2" value="3008"/>
                    <count group_id="O3" value="4001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4"/>
                    <measurement group_id="O2" value="68.3"/>
                    <measurement group_id="O3" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="962"/>
                    <count group_id="O2" value="2874"/>
                    <count group_id="O3" value="3836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1"/>
                    <measurement group_id="O2" value="70.0"/>
                    <measurement group_id="O3" value="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="923"/>
                    <count group_id="O2" value="2761"/>
                    <count group_id="O3" value="3684"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0"/>
                    <measurement group_id="O2" value="70.0"/>
                    <measurement group_id="O3" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="899"/>
                    <count group_id="O2" value="2654"/>
                    <count group_id="O3" value="3553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="71.7"/>
                    <measurement group_id="O3" value="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="856"/>
                    <count group_id="O2" value="2556"/>
                    <count group_id="O3" value="3412"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5"/>
                    <measurement group_id="O2" value="72.5"/>
                    <measurement group_id="O3" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="813"/>
                    <count group_id="O2" value="2456"/>
                    <count group_id="O3" value="3269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7"/>
                    <measurement group_id="O2" value="72.5"/>
                    <measurement group_id="O3" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="793"/>
                    <count group_id="O2" value="2345"/>
                    <count group_id="O3" value="3138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6"/>
                    <measurement group_id="O2" value="73.0"/>
                    <measurement group_id="O3" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="766"/>
                    <count group_id="O2" value="2271"/>
                    <count group_id="O3" value="3037"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="745"/>
                    <count group_id="O2" value="2209"/>
                    <count group_id="O3" value="2954"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="74.5"/>
                    <measurement group_id="O3" value="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="724"/>
                    <count group_id="O2" value="2142"/>
                    <count group_id="O3" value="2866"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="73.4"/>
                    <measurement group_id="O3" value="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="686"/>
                    <count group_id="O2" value="2057"/>
                    <count group_id="O3" value="2743"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                    <measurement group_id="O2" value="74.6"/>
                    <measurement group_id="O3" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="653"/>
                    <count group_id="O2" value="1893"/>
                    <count group_id="O3" value="2546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="74.7"/>
                    <measurement group_id="O3" value="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="611"/>
                    <count group_id="O2" value="1644"/>
                    <count group_id="O3" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6"/>
                    <measurement group_id="O2" value="75.2"/>
                    <measurement group_id="O3" value="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="579"/>
                    <count group_id="O2" value="1469"/>
                    <count group_id="O3" value="2048"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="487"/>
                    <count group_id="O2" value="1348"/>
                    <count group_id="O3" value="1835"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3"/>
                    <measurement group_id="O2" value="75.1"/>
                    <measurement group_id="O3" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="1198"/>
                    <count group_id="O3" value="1666"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="76.4"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="1011"/>
                    <count group_id="O3" value="1450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6"/>
                    <measurement group_id="O2" value="75.2"/>
                    <measurement group_id="O3" value="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="913"/>
                    <count group_id="O3" value="1320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                    <measurement group_id="O2" value="77.0"/>
                    <measurement group_id="O3" value="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="824"/>
                    <count group_id="O3" value="1214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8"/>
                    <measurement group_id="O2" value="76.5"/>
                    <measurement group_id="O3" value="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="702"/>
                    <count group_id="O3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5"/>
                    <measurement group_id="O2" value="78.1"/>
                    <measurement group_id="O3" value="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="355"/>
                    <count group_id="O2" value="483"/>
                    <count group_id="O3" value="838"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9"/>
                    <measurement group_id="O2" value="77.0"/>
                    <measurement group_id="O3" value="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="337"/>
                    <count group_id="O2" value="285"/>
                    <count group_id="O3" value="622"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8"/>
                    <measurement group_id="O2" value="73.3"/>
                    <measurement group_id="O3" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0"/>
                    <measurement group_id="O2" value="72.9"/>
                    <measurement group_id="O3" value="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3"/>
                    <measurement group_id="O2" value="70.3"/>
                    <measurement group_id="O3" value="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8"/>
                    <measurement group_id="O2" value="68.5"/>
                    <measurement group_id="O3" value="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2"/>
                    <measurement group_id="O2" value="68.2"/>
                    <measurement group_id="O3" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-4 (CRP) &lt;/=3.2 Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1"/>
                    <measurement group_id="O2" value="70.7"/>
                    <measurement group_id="O3" value="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="74.4"/>
                    <measurement group_id="O3" value="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="67.9"/>
                    <measurement group_id="O3" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6"/>
                    <measurement group_id="O2" value="81.8"/>
                    <measurement group_id="O3" value="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-3 (CRP) &lt;/=3.2 Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire – Disability Index (HAQ-DI) Score</title>
        <description>Change from baseline by visit. HAQ-DI scores range from 0 to 3, where lower score implies less disease. A reduction from baseline in score indicates an improvement in condition. A clinically meaningful decrease from baseline is defined as a decrease of at least 0.22 units.
The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
        <time_frame>Every visit until study completion</time_frame>
        <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligram (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire – Disability Index (HAQ-DI) Score</title>
          <description>Change from baseline by visit. HAQ-DI scores range from 0 to 3, where lower score implies less disease. A reduction from baseline in score indicates an improvement in condition. A clinically meaningful decrease from baseline is defined as a decrease of at least 0.22 units.
The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
          <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1098"/>
                    <count group_id="O2" value="3264"/>
                    <count group_id="O3" value="4362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.62"/>
                    <measurement group_id="O2" value="-0.61" spread="0.63"/>
                    <measurement group_id="O3" value="-0.60" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1067"/>
                    <count group_id="O2" value="3213"/>
                    <count group_id="O3" value="4280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.62"/>
                    <measurement group_id="O2" value="-0.65" spread="0.65"/>
                    <measurement group_id="O3" value="-0.63" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1057"/>
                    <count group_id="O2" value="3196"/>
                    <count group_id="O3" value="4253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.63"/>
                    <measurement group_id="O2" value="-0.66" spread="0.65"/>
                    <measurement group_id="O3" value="-0.64" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1029"/>
                    <count group_id="O2" value="3105"/>
                    <count group_id="O3" value="4134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.65"/>
                    <measurement group_id="O2" value="-0.65" spread="0.66"/>
                    <measurement group_id="O3" value="-0.64" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="990"/>
                    <count group_id="O2" value="2992"/>
                    <count group_id="O3" value="3982"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.64"/>
                    <measurement group_id="O2" value="-0.66" spread="0.66"/>
                    <measurement group_id="O3" value="-0.64" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="960"/>
                    <count group_id="O2" value="2866"/>
                    <count group_id="O3" value="3826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.65"/>
                    <measurement group_id="O2" value="-0.66" spread="0.67"/>
                    <measurement group_id="O3" value="-0.64" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="926"/>
                    <count group_id="O2" value="2756"/>
                    <count group_id="O3" value="3682"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.65"/>
                    <measurement group_id="O2" value="-0.68" spread="0.68"/>
                    <measurement group_id="O3" value="-0.66" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="898"/>
                    <count group_id="O2" value="2646"/>
                    <count group_id="O3" value="3544"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.65"/>
                    <measurement group_id="O2" value="-0.68" spread="0.67"/>
                    <measurement group_id="O3" value="-0.66" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="849"/>
                    <count group_id="O2" value="2542"/>
                    <count group_id="O3" value="3391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.67"/>
                    <measurement group_id="O2" value="-0.69" spread="0.68"/>
                    <measurement group_id="O3" value="-0.67" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="815"/>
                    <count group_id="O2" value="2443"/>
                    <count group_id="O3" value="3258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.65"/>
                    <measurement group_id="O2" value="-0.69" spread="0.68"/>
                    <measurement group_id="O3" value="-0.67" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="789"/>
                    <count group_id="O2" value="2341"/>
                    <count group_id="O3" value="3130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.65"/>
                    <measurement group_id="O2" value="-0.69" spread="0.68"/>
                    <measurement group_id="O3" value="-0.67" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="757"/>
                    <count group_id="O2" value="2258"/>
                    <count group_id="O3" value="3015"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.66"/>
                    <measurement group_id="O2" value="-0.68" spread="0.69"/>
                    <measurement group_id="O3" value="-0.66" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="741"/>
                    <count group_id="O2" value="2194"/>
                    <count group_id="O3" value="2935"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.66"/>
                    <measurement group_id="O2" value="-0.67" spread="0.69"/>
                    <measurement group_id="O3" value="-0.66" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="720"/>
                    <count group_id="O2" value="2136"/>
                    <count group_id="O3" value="2856"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.66"/>
                    <measurement group_id="O2" value="-0.67" spread="0.68"/>
                    <measurement group_id="O3" value="-0.66" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="683"/>
                    <count group_id="O2" value="2053"/>
                    <count group_id="O3" value="2736"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.67"/>
                    <measurement group_id="O2" value="-0.68" spread="0.69"/>
                    <measurement group_id="O3" value="-0.66" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="649"/>
                    <count group_id="O2" value="1884"/>
                    <count group_id="O3" value="2533"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.67"/>
                    <measurement group_id="O2" value="-0.66" spread="0.68"/>
                    <measurement group_id="O3" value="-0.65" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="1636"/>
                    <count group_id="O3" value="2245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.69"/>
                    <measurement group_id="O2" value="-0.64" spread="0.69"/>
                    <measurement group_id="O3" value="-0.63" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="575"/>
                    <count group_id="O2" value="1468"/>
                    <count group_id="O3" value="2043"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.69"/>
                    <measurement group_id="O2" value="-0.64" spread="0.69"/>
                    <measurement group_id="O3" value="-0.62" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="482"/>
                    <count group_id="O2" value="1332"/>
                    <count group_id="O3" value="1814"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.69"/>
                    <measurement group_id="O2" value="-0.63" spread="0.66"/>
                    <measurement group_id="O3" value="-0.62" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="463"/>
                    <count group_id="O2" value="1191"/>
                    <count group_id="O3" value="1654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.68"/>
                    <measurement group_id="O2" value="-0.65" spread="0.67"/>
                    <measurement group_id="O3" value="-0.63" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="434"/>
                    <count group_id="O2" value="1011"/>
                    <count group_id="O3" value="1445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.69"/>
                    <measurement group_id="O2" value="-0.66" spread="0.68"/>
                    <measurement group_id="O3" value="-0.63" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="405"/>
                    <count group_id="O2" value="916"/>
                    <count group_id="O3" value="1321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.68"/>
                    <measurement group_id="O2" value="-0.66" spread="0.69"/>
                    <measurement group_id="O3" value="-0.64" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="828"/>
                    <count group_id="O3" value="1220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.68"/>
                    <measurement group_id="O2" value="-0.68" spread="0.70"/>
                    <measurement group_id="O3" value="-0.64" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="702"/>
                    <count group_id="O3" value="1077"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.70"/>
                    <measurement group_id="O2" value="-0.67" spread="0.69"/>
                    <measurement group_id="O3" value="-0.63" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="353"/>
                    <count group_id="O2" value="484"/>
                    <count group_id="O3" value="837"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.70"/>
                    <measurement group_id="O2" value="-0.66" spread="0.71"/>
                    <measurement group_id="O3" value="-0.61" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="286"/>
                    <count group_id="O3" value="621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.71"/>
                    <measurement group_id="O2" value="-0.62" spread="0.73"/>
                    <measurement group_id="O3" value="-0.59" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="303"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.72"/>
                    <measurement group_id="O2" value="-0.58" spread="0.73"/>
                    <measurement group_id="O3" value="-0.57" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="380"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.73"/>
                    <measurement group_id="O2" value="-0.61" spread="0.78"/>
                    <measurement group_id="O3" value="-0.56" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.73"/>
                    <measurement group_id="O2" value="-0.64" spread="0.68"/>
                    <measurement group_id="O3" value="-0.56" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.73"/>
                    <measurement group_id="O2" value="-0.56" spread="0.68"/>
                    <measurement group_id="O3" value="-0.53" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="262"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.70"/>
                    <measurement group_id="O2" value="-0.53" spread="0.60"/>
                    <measurement group_id="O3" value="-0.53" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.72"/>
                    <measurement group_id="O2" value="-0.54" spread="0.61"/>
                    <measurement group_id="O3" value="-0.52" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.75"/>
                    <measurement group_id="O2" value="-0.50" spread="0.60"/>
                    <measurement group_id="O3" value="-0.52" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.77"/>
                    <measurement group_id="O2" value="-0.48" spread="0.58"/>
                    <measurement group_id="O3" value="-0.53" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.80"/>
                    <measurement group_id="O2" value="-0.44" spread="0.51"/>
                    <measurement group_id="O3" value="-0.52" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.82"/>
                    <measurement group_id="O2" value="-0.29" spread="0.85"/>
                    <measurement group_id="O3" value="-0.58" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.91"/>
                    <measurement group_id="O2" value="-0.50" spread="0.99"/>
                    <measurement group_id="O3" value="-0.63" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="0.97"/>
                    <measurement group_id="O2" value="0.13" spread="0"/>
                    <measurement group_id="O3" value="-0.78" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 111</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="1.34"/>
                    <measurement group_id="O2" value="0.25" spread="0"/>
                    <measurement group_id="O3" value="-0.91" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 114</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0"/>
                    <measurement group_id="O3" value="-0.13" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-Form-36 Health Survey (SF-36) Score</title>
        <description>Change from Baseline for Physical Component and Mental Component Scores by visit. SF-36 is a health status measure of 8 general health domains, each scored on a 0 to 100 scale: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These domains can be summarized as physical and mental component scores. The domain scores were &quot;normed&quot; and the resulting component scores treated as Z-scores with a scale of negative to positive infinity. A higher score implies less disease. The greater the change from baseline, the greater the improvement. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
        <time_frame>Every visit until study completion</time_frame>
        <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>Short-Form-36 Health Survey (SF-36) Score</title>
          <description>Change from Baseline for Physical Component and Mental Component Scores by visit. SF-36 is a health status measure of 8 general health domains, each scored on a 0 to 100 scale: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These domains can be summarized as physical and mental component scores. The domain scores were &quot;normed&quot; and the resulting component scores treated as Z-scores with a scale of negative to positive infinity. A higher score implies less disease. The greater the change from baseline, the greater the improvement. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
          <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
          <units>Scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="983"/>
                    <count group_id="O2" value="2693"/>
                    <count group_id="O3" value="3676"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.90" spread="8.70"/>
                    <measurement group_id="O2" value="8.85" spread="8.92"/>
                    <measurement group_id="O3" value="8.60" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="961"/>
                    <count group_id="O2" value="2629"/>
                    <count group_id="O3" value="3590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.10" spread="8.94"/>
                    <measurement group_id="O2" value="9.02" spread="9.11"/>
                    <measurement group_id="O3" value="8.77" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="2499"/>
                    <count group_id="O3" value="3033"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.60" spread="9.07"/>
                    <measurement group_id="O2" value="8.80" spread="9.20"/>
                    <measurement group_id="O3" value="8.77" spread="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="903"/>
                    <count group_id="O2" value="2449"/>
                    <count group_id="O3" value="3352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" spread="8.53"/>
                    <measurement group_id="O2" value="8.78" spread="9.26"/>
                    <measurement group_id="O3" value="8.69" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="733"/>
                    <count group_id="O2" value="2324"/>
                    <count group_id="O3" value="3057"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" spread="8.88"/>
                    <measurement group_id="O2" value="8.98" spread="9.05"/>
                    <measurement group_id="O3" value="8.85" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="855"/>
                    <count group_id="O2" value="2188"/>
                    <count group_id="O3" value="3043"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" spread="8.89"/>
                    <measurement group_id="O2" value="8.99" spread="9.18"/>
                    <measurement group_id="O3" value="8.75" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="767"/>
                    <count group_id="O2" value="2005"/>
                    <count group_id="O3" value="2772"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="8.70"/>
                    <measurement group_id="O2" value="8.85" spread="8.96"/>
                    <measurement group_id="O3" value="8.62" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="797"/>
                    <count group_id="O2" value="2102"/>
                    <count group_id="O3" value="2899"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.28" spread="8.73"/>
                    <measurement group_id="O2" value="9.00" spread="9.30"/>
                    <measurement group_id="O3" value="8.80" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="739"/>
                    <count group_id="O2" value="1663"/>
                    <count group_id="O3" value="2402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.41" spread="8.84"/>
                    <measurement group_id="O2" value="8.64" spread="9.16"/>
                    <measurement group_id="O3" value="8.57" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="708"/>
                    <count group_id="O2" value="1566"/>
                    <count group_id="O3" value="2274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" spread="8.81"/>
                    <measurement group_id="O2" value="8.56" spread="9.06"/>
                    <measurement group_id="O3" value="8.32" spread="8.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="682"/>
                    <count group_id="O2" value="1444"/>
                    <count group_id="O3" value="2126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="8.87"/>
                    <measurement group_id="O2" value="8.39" spread="9.31"/>
                    <measurement group_id="O3" value="8.32" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="1530"/>
                    <count group_id="O3" value="2206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.31" spread="8.97"/>
                    <measurement group_id="O2" value="8.43" spread="9.22"/>
                    <measurement group_id="O3" value="8.40" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="1176"/>
                    <count group_id="O3" value="1785"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05" spread="9.26"/>
                    <measurement group_id="O2" value="8.13" spread="9.14"/>
                    <measurement group_id="O3" value="8.10" spread="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="573"/>
                    <count group_id="O2" value="923"/>
                    <count group_id="O3" value="1496"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" spread="9.32"/>
                    <measurement group_id="O2" value="8.07" spread="9.13"/>
                    <measurement group_id="O3" value="7.97" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="540"/>
                    <count group_id="O2" value="652"/>
                    <count group_id="O3" value="1192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.40" spread="9.87"/>
                    <measurement group_id="O2" value="8.33" spread="9.40"/>
                    <measurement group_id="O3" value="8.36" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="537"/>
                    <count group_id="O2" value="1044"/>
                    <count group_id="O3" value="1581"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.12" spread="9.56"/>
                    <measurement group_id="O2" value="8.27" spread="9.23"/>
                    <measurement group_id="O3" value="8.22" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="304"/>
                    <count group_id="O3" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" spread="9.69"/>
                    <measurement group_id="O2" value="8.55" spread="9.70"/>
                    <measurement group_id="O3" value="8.16" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="175"/>
                    <count group_id="O3" value="571"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.72" spread="9.41"/>
                    <measurement group_id="O2" value="8.82" spread="9.47"/>
                    <measurement group_id="O3" value="8.06" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.57" spread="9.72"/>
                    <measurement group_id="O2" value="8.12" spread="9.69"/>
                    <measurement group_id="O3" value="7.69" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="259"/>
                    <count group_id="O3" value="630"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" spread="9.74"/>
                    <measurement group_id="O2" value="9.29" spread="9.43"/>
                    <measurement group_id="O3" value="8.49" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="345"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.73" spread="9.76"/>
                    <measurement group_id="O2" value="7.90" spread="8.98"/>
                    <measurement group_id="O3" value="7.76" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" spread="9.41"/>
                    <measurement group_id="O2" value="7.58" spread="7.88"/>
                    <measurement group_id="O3" value="7.87" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68" spread="9.32"/>
                    <measurement group_id="O2" value="9.12" spread="7.06"/>
                    <measurement group_id="O3" value="7.87" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="316"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.90" spread="9.93"/>
                    <measurement group_id="O2" value="8.70" spread="10.24"/>
                    <measurement group_id="O3" value="8.02" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" spread="10.96"/>
                    <measurement group_id="O2" value="5.75" spread="9.05"/>
                    <measurement group_id="O3" value="8.62" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.22" spread="11.10"/>
                    <measurement group_id="O2" value="7.39" spread="7.09"/>
                    <measurement group_id="O3" value="9.90" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.51" spread="10.17"/>
                    <measurement group_id="O2" value="7.90" spread="13.05"/>
                    <measurement group_id="O3" value="10.31" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.93" spread="11.56"/>
                    <measurement group_id="O2" value="7.14" spread="8.01"/>
                    <measurement group_id="O3" value="8.74" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.92" spread="10.49"/>
                    <measurement group_id="O2" value="15.23" spread="3.64"/>
                    <measurement group_id="O3" value="12.16" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.50" spread="10.98"/>
                    <measurement group_id="O2" value="16.50" spread="0"/>
                    <measurement group_id="O3" value="13.73" spread="10.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.71" spread="0"/>
                    <measurement group_id="O3" value="26.71" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="9.75"/>
                    <measurement group_id="O3" value="4.61" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.26" spread="0"/>
                    <measurement group_id="O3" value="-8.26" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="983"/>
                    <count group_id="O2" value="2693"/>
                    <count group_id="O3" value="3676"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="10.88"/>
                    <measurement group_id="O2" value="4.91" spread="11.18"/>
                    <measurement group_id="O3" value="4.77" spread="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="961"/>
                    <count group_id="O2" value="2629"/>
                    <count group_id="O3" value="3590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="10.85"/>
                    <measurement group_id="O2" value="4.81" spread="11.12"/>
                    <measurement group_id="O3" value="4.58" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="2499"/>
                    <count group_id="O3" value="3033"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="10.78"/>
                    <measurement group_id="O2" value="5.04" spread="11.17"/>
                    <measurement group_id="O3" value="4.97" spread="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="903"/>
                    <count group_id="O2" value="2449"/>
                    <count group_id="O3" value="3352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="11.03"/>
                    <measurement group_id="O2" value="4.81" spread="11.43"/>
                    <measurement group_id="O3" value="4.53" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="733"/>
                    <count group_id="O2" value="2324"/>
                    <count group_id="O3" value="3057"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="11.21"/>
                    <measurement group_id="O2" value="4.79" spread="11.52"/>
                    <measurement group_id="O3" value="4.63" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="855"/>
                    <count group_id="O2" value="2188"/>
                    <count group_id="O3" value="3043"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="11.11"/>
                    <measurement group_id="O2" value="4.87" spread="11.41"/>
                    <measurement group_id="O3" value="4.66" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="767"/>
                    <count group_id="O2" value="2005"/>
                    <count group_id="O3" value="2772"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="11.08"/>
                    <measurement group_id="O2" value="4.87" spread="11.22"/>
                    <measurement group_id="O3" value="4.68" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="797"/>
                    <count group_id="O2" value="2102"/>
                    <count group_id="O3" value="2899"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="11.06"/>
                    <measurement group_id="O2" value="5.08" spread="11.32"/>
                    <measurement group_id="O3" value="4.82" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="739"/>
                    <count group_id="O2" value="1663"/>
                    <count group_id="O3" value="2402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="10.53"/>
                    <measurement group_id="O2" value="4.91" spread="11.28"/>
                    <measurement group_id="O3" value="4.53" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="708"/>
                    <count group_id="O2" value="1566"/>
                    <count group_id="O3" value="2274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="11.14"/>
                    <measurement group_id="O2" value="4.68" spread="11.71"/>
                    <measurement group_id="O3" value="4.34" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="682"/>
                    <count group_id="O2" value="1444"/>
                    <count group_id="O3" value="2126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="10.65"/>
                    <measurement group_id="O2" value="4.82" spread="11.74"/>
                    <measurement group_id="O3" value="4.53" spread="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="1530"/>
                    <count group_id="O3" value="2206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="10.94"/>
                    <measurement group_id="O2" value="4.81" spread="11.60"/>
                    <measurement group_id="O3" value="4.51" spread="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="1176"/>
                    <count group_id="O3" value="1785"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="11.02"/>
                    <measurement group_id="O2" value="4.59" spread="11.75"/>
                    <measurement group_id="O3" value="4.25" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="573"/>
                    <count group_id="O2" value="923"/>
                    <count group_id="O3" value="1496"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="11.40"/>
                    <measurement group_id="O2" value="4.55" spread="11.63"/>
                    <measurement group_id="O3" value="4.04" spread="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="540"/>
                    <count group_id="O2" value="652"/>
                    <count group_id="O3" value="1192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="11.63"/>
                    <measurement group_id="O2" value="4.40" spread="11.64"/>
                    <measurement group_id="O3" value="3.83" spread="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="537"/>
                    <count group_id="O2" value="1044"/>
                    <count group_id="O3" value="1581"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="11.71"/>
                    <measurement group_id="O2" value="4.73" spread="11.83"/>
                    <measurement group_id="O3" value="4.31" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="304"/>
                    <count group_id="O3" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="12.12"/>
                    <measurement group_id="O2" value="4.83" spread="11.82"/>
                    <measurement group_id="O3" value="4.13" spread="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="175"/>
                    <count group_id="O3" value="571"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="11.77"/>
                    <measurement group_id="O2" value="6.49" spread="12.67"/>
                    <measurement group_id="O3" value="4.38" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="12.24"/>
                    <measurement group_id="O2" value="5.10" spread="11.74"/>
                    <measurement group_id="O3" value="3.65" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="259"/>
                    <count group_id="O3" value="630"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="12.06"/>
                    <measurement group_id="O2" value="5.18" spread="12.22"/>
                    <measurement group_id="O3" value="3.93" spread="12.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="345"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="11.61"/>
                    <measurement group_id="O2" value="4.22" spread="10.32"/>
                    <measurement group_id="O3" value="3.23" spread="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="11.32"/>
                    <measurement group_id="O2" value="3.47" spread="8.33"/>
                    <measurement group_id="O3" value="3.04" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="12.35"/>
                    <measurement group_id="O2" value="4.90" spread="9.84"/>
                    <measurement group_id="O3" value="4.03" spread="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="316"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="11.48"/>
                    <measurement group_id="O2" value="5.32" spread="12.80"/>
                    <measurement group_id="O3" value="4.00" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="12.22"/>
                    <measurement group_id="O2" value="1.52" spread="11.38"/>
                    <measurement group_id="O3" value="4.60" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="13.37"/>
                    <measurement group_id="O2" value="1.05" spread="13.28"/>
                    <measurement group_id="O3" value="3.77" spread="13.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="10.40"/>
                    <measurement group_id="O2" value="2.60" spread="14.75"/>
                    <measurement group_id="O3" value="5.83" spread="10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="13.07"/>
                    <measurement group_id="O2" value="-2.36" spread="11.63"/>
                    <measurement group_id="O3" value="4.87" spread="13.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 87</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.52" spread="13.03"/>
                    <measurement group_id="O2" value="16.93" spread="2.66"/>
                    <measurement group_id="O3" value="8.19" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="11.75"/>
                    <measurement group_id="O2" value="18.75" spread="0"/>
                    <measurement group_id="O3" value="5.65" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.03" spread="0"/>
                    <measurement group_id="O3" value="14.03" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" spread="9.73"/>
                    <measurement group_id="O3" value="7.58" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Month 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.28" spread="0"/>
                    <measurement group_id="O3" value="22.28" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FACIT Fatigue Scale, EuroQol EQ 5D, Work Limitations Questionnaire, and RA Healthcare Resource Utilization Questionnaire (RA-HCRU)</title>
        <description>Change from Baseline Scores for each: FACIT Fatigue Scale (score range 0 to 52, higher score indicates higher quality of life and an increase from baseline score indicates improvement), EuroQol EQ 5D (index values derived from a measure of central tendency and a measure of dispersion, an increase from baseline indicates improvement, score range 0 to 1), Work Limitations (WL) Physical Demands (covers ability to perform job tasks that involve bodily strength, a decrease from baseline indicates improvement, score range 0 to 100, higher scores indicating greater limitation), and RA Healthcare Resource Utilization Work Performance in Past 3 Months on Days Bothered by RA (assesses healthcare use over previous 3 months, a decrease from baseline indicates improvement, score range 0 to 10).
The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
        <time_frame>Every visit until study completion</time_frame>
        <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>FACIT Fatigue Scale, EuroQol EQ 5D, Work Limitations Questionnaire, and RA Healthcare Resource Utilization Questionnaire (RA-HCRU)</title>
          <description>Change from Baseline Scores for each: FACIT Fatigue Scale (score range 0 to 52, higher score indicates higher quality of life and an increase from baseline score indicates improvement), EuroQol EQ 5D (index values derived from a measure of central tendency and a measure of dispersion, an increase from baseline indicates improvement, score range 0 to 1), Work Limitations (WL) Physical Demands (covers ability to perform job tasks that involve bodily strength, a decrease from baseline indicates improvement, score range 0 to 100, higher scores indicating greater limitation), and RA Healthcare Resource Utilization Work Performance in Past 3 Months on Days Bothered by RA (assesses healthcare use over previous 3 months, a decrease from baseline indicates improvement, score range 0 to 10).
The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.</description>
          <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FACIT Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="370"/>
                    <count group_id="O2" value="2544"/>
                    <count group_id="O3" value="2914"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" spread="8.98"/>
                    <measurement group_id="O2" value="7.33" spread="10.57"/>
                    <measurement group_id="O3" value="7.19" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="582"/>
                    <count group_id="O2" value="2396"/>
                    <count group_id="O3" value="2978"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="9.74"/>
                    <measurement group_id="O2" value="7.33" spread="10.56"/>
                    <measurement group_id="O3" value="7.06" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="729"/>
                    <count group_id="O2" value="2168"/>
                    <count group_id="O3" value="2897"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.14" spread="10.06"/>
                    <measurement group_id="O2" value="7.40" spread="10.65"/>
                    <measurement group_id="O3" value="7.09" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="2053"/>
                    <count group_id="O3" value="2757"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.90" spread="9.76"/>
                    <measurement group_id="O2" value="7.42" spread="10.56"/>
                    <measurement group_id="O3" value="7.03" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="618"/>
                    <count group_id="O2" value="1525"/>
                    <count group_id="O3" value="2143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" spread="10.08"/>
                    <measurement group_id="O2" value="7.00" spread="10.91"/>
                    <measurement group_id="O3" value="6.52" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="589"/>
                    <count group_id="O2" value="1497"/>
                    <count group_id="O3" value="2086"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.95" spread="9.87"/>
                    <measurement group_id="O2" value="6.87" spread="10.94"/>
                    <measurement group_id="O3" value="6.61" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="491"/>
                    <count group_id="O2" value="898"/>
                    <count group_id="O3" value="1389"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="10.36"/>
                    <measurement group_id="O2" value="6.83" spread="10.86"/>
                    <measurement group_id="O3" value="6.31" spread="10.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="1025"/>
                    <count group_id="O3" value="1489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" spread="10.33"/>
                    <measurement group_id="O2" value="6.88" spread="10.95"/>
                    <measurement group_id="O3" value="6.61" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="10.49"/>
                    <measurement group_id="O2" value="8.51" spread="11.58"/>
                    <measurement group_id="O3" value="6.96" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                    <count group_id="O2" value="256"/>
                    <count group_id="O3" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.96" spread="10.69"/>
                    <measurement group_id="O2" value="8.88" spread="11.65"/>
                    <measurement group_id="O3" value="7.27" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64" spread="10.93"/>
                    <measurement group_id="O2" value="6.67" spread="10.58"/>
                    <measurement group_id="O3" value="5.81" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="11.10"/>
                    <measurement group_id="O2" value="8.63" spread="10.71"/>
                    <measurement group_id="O3" value="6.18" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.06" spread="11.15"/>
                    <measurement group_id="O2" value="0.71" spread="14.84"/>
                    <measurement group_id="O3" value="10.03" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" spread="12.88"/>
                    <measurement group_id="O2" value="2.91" spread="12.36"/>
                    <measurement group_id="O3" value="8.32" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.67" spread="9.14"/>
                    <measurement group_id="O2" value="10.00" spread="0"/>
                    <measurement group_id="O3" value="17.43" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACIT Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="2.65"/>
                    <measurement group_id="O3" value="6.00" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="323"/>
                    <count group_id="O2" value="2021"/>
                    <count group_id="O3" value="2344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.31"/>
                    <measurement group_id="O2" value="0.22" spread="0.32"/>
                    <measurement group_id="O3" value="0.22" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="538"/>
                    <count group_id="O2" value="1897"/>
                    <count group_id="O3" value="2435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.30"/>
                    <measurement group_id="O2" value="0.22" spread="0.33"/>
                    <measurement group_id="O3" value="0.22" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="684"/>
                    <count group_id="O2" value="1748"/>
                    <count group_id="O3" value="2432"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.32"/>
                    <measurement group_id="O2" value="0.23" spread="0.33"/>
                    <measurement group_id="O3" value="0.22" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="664"/>
                    <count group_id="O2" value="1619"/>
                    <count group_id="O3" value="2283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.31"/>
                    <measurement group_id="O2" value="0.23" spread="0.33"/>
                    <measurement group_id="O3" value="0.22" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="616"/>
                    <count group_id="O2" value="1456"/>
                    <count group_id="O3" value="2072"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.31"/>
                    <measurement group_id="O2" value="0.22" spread="0.33"/>
                    <measurement group_id="O3" value="0.21" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="582"/>
                    <count group_id="O2" value="1397"/>
                    <count group_id="O3" value="1979"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.30"/>
                    <measurement group_id="O2" value="0.23" spread="0.33"/>
                    <measurement group_id="O3" value="0.22" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="483"/>
                    <count group_id="O2" value="874"/>
                    <count group_id="O3" value="1357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.31"/>
                    <measurement group_id="O2" value="0.24" spread="0.33"/>
                    <measurement group_id="O3" value="0.22" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="1010"/>
                    <count group_id="O3" value="1474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.31"/>
                    <measurement group_id="O2" value="0.23" spread="0.33"/>
                    <measurement group_id="O3" value="0.22" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="497"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.32"/>
                    <measurement group_id="O2" value="0.32" spread="0.36"/>
                    <measurement group_id="O3" value="0.22" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="255"/>
                    <count group_id="O3" value="572"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.33"/>
                    <measurement group_id="O2" value="0.27" spread="0.35"/>
                    <measurement group_id="O3" value="0.23" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.33"/>
                    <measurement group_id="O2" value="0.24" spread="0.34"/>
                    <measurement group_id="O3" value="0.21" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.32"/>
                    <measurement group_id="O2" value="0.28" spread="0.35"/>
                    <measurement group_id="O3" value="0.23" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.37"/>
                    <measurement group_id="O2" value="0.10" spread="0.51"/>
                    <measurement group_id="O3" value="0.31" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.35"/>
                    <measurement group_id="O2" value="0.21" spread="0.43"/>
                    <measurement group_id="O3" value="0.27" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.32"/>
                    <measurement group_id="O2" value="0.84" spread="0"/>
                    <measurement group_id="O3" value="0.52" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EuroQol Month 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.04"/>
                    <measurement group_id="O3" value="0.09" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="900"/>
                    <count group_id="O3" value="1009"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.34" spread="39.81"/>
                    <measurement group_id="O2" value="-3.67" spread="38.17"/>
                    <measurement group_id="O3" value="-3.85" spread="38.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="808"/>
                    <count group_id="O3" value="904"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.31" spread="37.81"/>
                    <measurement group_id="O2" value="-4.02" spread="39.25"/>
                    <measurement group_id="O3" value="-4.16" spread="39.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="706"/>
                    <count group_id="O3" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.97" spread="35.46"/>
                    <measurement group_id="O2" value="-2.29" spread="37.48"/>
                    <measurement group_id="O3" value="-2.89" spread="37.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="544"/>
                    <count group_id="O3" value="607"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.62" spread="36.05"/>
                    <measurement group_id="O2" value="-4.46" spread="37.54"/>
                    <measurement group_id="O3" value="-4.27" spread="37.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="444"/>
                    <count group_id="O3" value="495"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.12" spread="37.17"/>
                    <measurement group_id="O2" value="-3.75" spread="37.67"/>
                    <measurement group_id="O3" value="-4.41" spread="37.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="350"/>
                    <count group_id="O3" value="385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.31" spread="34.69"/>
                    <measurement group_id="O2" value="-3.95" spread="39.58"/>
                    <measurement group_id="O3" value="-4.25" spread="39.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.51" spread="33.91"/>
                    <measurement group_id="O2" value="-4.81" spread="38.98"/>
                    <measurement group_id="O3" value="-5.58" spread="38.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="126"/>
                    <count group_id="O3" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.86" spread="34.47"/>
                    <measurement group_id="O2" value="0.73" spread="38.68"/>
                    <measurement group_id="O3" value="-2.76" spread="39.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.17" spread="62.46"/>
                    <measurement group_id="O2" value="-13.27" spread="45.69"/>
                    <measurement group_id="O3" value="-15.63" spread="46.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-27.78" spread="34.94"/>
                    <measurement group_id="O3" value="-27.78" spread="34.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WL: Physical Demands Month 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.33" spread="0"/>
                    <measurement group_id="O3" value="8.33" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="1419"/>
                    <count group_id="O3" value="1608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="6.20"/>
                    <measurement group_id="O2" value="-2.08" spread="4.15"/>
                    <measurement group_id="O3" value="-2.07" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="1329"/>
                    <count group_id="O3" value="1509"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.41" spread="6.43"/>
                    <measurement group_id="O2" value="-2.26" spread="3.76"/>
                    <measurement group_id="O3" value="-2.28" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="1162"/>
                    <count group_id="O3" value="1323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="2.93"/>
                    <measurement group_id="O2" value="-2.24" spread="3.90"/>
                    <measurement group_id="O3" value="-2.19" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="1101"/>
                    <count group_id="O3" value="1263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="3.18"/>
                    <measurement group_id="O2" value="-2.22" spread="3.26"/>
                    <measurement group_id="O3" value="-2.19" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="785"/>
                    <count group_id="O3" value="911"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="3.02"/>
                    <measurement group_id="O2" value="-2.16" spread="4.17"/>
                    <measurement group_id="O3" value="-2.10" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="759"/>
                    <count group_id="O3" value="865"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="2.91"/>
                    <measurement group_id="O2" value="-2.32" spread="4.14"/>
                    <measurement group_id="O3" value="-2.33" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="455"/>
                    <count group_id="O3" value="523"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="2.84"/>
                    <measurement group_id="O2" value="-2.18" spread="4.70"/>
                    <measurement group_id="O3" value="-2.11" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="527"/>
                    <count group_id="O3" value="593"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="3.24"/>
                    <measurement group_id="O2" value="-2.15" spread="4.67"/>
                    <measurement group_id="O3" value="-2.12" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.00"/>
                    <measurement group_id="O2" value="-2.59" spread="3.42"/>
                    <measurement group_id="O3" value="-2.55" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="3.56"/>
                    <measurement group_id="O2" value="-2.88" spread="2.85"/>
                    <measurement group_id="O3" value="-2.85" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-HCRU Month 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.25" spread="6.70"/>
                    <measurement group_id="O3" value="-1.25" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preservation of Joint Structure in Participants Who Had Baseline Radiographs Obtained in Their Qualifying Index Study</title>
        <description>Modified Total Sharp Score per visit. Baseline score was the last available assessment from the index study. The Modified Total Sharp Score measures disease progression; increased scores indicate disease progression. Score range 0 (normal) to 448 (worst possible total score). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
TSS=Total Sharp Score</description>
        <time_frame>Every 6 months until study completion</time_frame>
        <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 Milligrams (mg) Twice Daily (BID)</title>
            <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Participants with average total daily dose across study ≥15 were assigned to 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>All Tofacitinib</title>
            <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
          </group>
        </group_list>
        <measure>
          <title>Preservation of Joint Structure in Participants Who Had Baseline Radiographs Obtained in Their Qualifying Index Study</title>
          <description>Modified Total Sharp Score per visit. Baseline score was the last available assessment from the index study. The Modified Total Sharp Score measures disease progression; increased scores indicate disease progression. Score range 0 (normal) to 448 (worst possible total score). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
TSS=Total Sharp Score</description>
          <population>The number of participants analyzed is the number remaining in the study who had evaluable data for the measure at the given time point.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="3358"/>
                <count group_id="O3" value="4481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Modified TSS Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="1061"/>
                    <count group_id="O3" value="1156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.55" spread="33.37"/>
                    <measurement group_id="O2" value="24.13" spread="43.57"/>
                    <measurement group_id="O3" value="23.84" spread="42.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified TSS Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="937"/>
                    <count group_id="O3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.58" spread="35.10"/>
                    <measurement group_id="O2" value="25.12" spread="44.42"/>
                    <measurement group_id="O3" value="24.91" spread="43.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified TSS Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="918"/>
                    <count group_id="O3" value="1003"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.26" spread="33.75"/>
                    <measurement group_id="O2" value="24.73" spread="44.08"/>
                    <measurement group_id="O3" value="24.44" spread="43.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified TSS Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="801"/>
                    <count group_id="O3" value="878"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.07" spread="35.85"/>
                    <measurement group_id="O2" value="24.85" spread="43.21"/>
                    <measurement group_id="O3" value="24.61" spread="42.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified TSS Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="379"/>
                    <count group_id="O3" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.88" spread="37.74"/>
                    <measurement group_id="O2" value="28.22" spread="44.95"/>
                    <measurement group_id="O3" value="28.02" spread="44.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Pneumococcal Vaccine as Defined by ≥ 2-fold Increase in Antibody Concentrations</title>
        <description>Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg BID Continuous Visit 3</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted Visit 3</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
          <group group_id="O3">
            <title>Tofacitinib 10 mg BID Continuous Visit 4</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O4">
            <title>Tofacitinib 10 mg BID Interrupted Visit 4</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Pneumococcal Vaccine as Defined by ≥ 2-fold Increase in Antibody Concentrations</title>
          <description>Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="11.3" upper_limit="28.2"/>
                    <measurement group_id="O2" value="38.5" lower_limit="28.4" upper_limit="49.2"/>
                    <measurement group_id="O3" value="75.0" lower_limit="64.9" upper_limit="83.4"/>
                    <measurement group_id="O4" value="84.6" lower_limit="75.5" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Seasonal Influenza Vaccine as Defined by ≥ 4-fold Increase in Antibody Titers</title>
        <description>Number of participants achieving a satisfactory humoral response to the seasonal influenza vaccine as defined by ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg BID Continuous Visit 3</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted Visit 3</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
          <group group_id="O3">
            <title>Tofacitinib 10 mg BID Continuous Visit 4</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O4">
            <title>Tofacitinib 10 mg BID Interrupted Visit 4</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Seasonal Influenza Vaccine as Defined by ≥ 4-fold Increase in Antibody Titers</title>
          <description>Number of participants achieving a satisfactory humoral response to the seasonal influenza vaccine as defined by ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" lower_limit="22.5" upper_limit="42.5"/>
                    <measurement group_id="O2" value="53.8" lower_limit="43.1" upper_limit="64.4"/>
                    <measurement group_id="O3" value="66.3" lower_limit="55.7" upper_limit="75.8"/>
                    <measurement group_id="O4" value="63.7" lower_limit="53.0" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Percentage of Participants Achieving Protective Antibody Titers to the Seasonal Influenza Vaccine as Measured by a Hemagglutination Inhibition (HI) Assay Titer of ≥ 1:40 in ≥ 2 of 3 Influenza Antigens at Vaccine Sub-study Visit 3 and 4</title>
        <description>Number (%) of participants achieving protective antibody titers to the seasonal influenza vaccine as measured by an HAI assay titer of ≥1:40 in ≥2 of 3 influenza antigens measured at vaccine sub-study visits 3 and 4.
The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg BID Continuous Visit 3</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted Visit 3</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
          <group group_id="O3">
            <title>Tofacitinib 10 mg BID Continuous Visit 4</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O4">
            <title>Tofacitinib 10 mg BID Interrupted Visit 4</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Percentage of Participants Achieving Protective Antibody Titers to the Seasonal Influenza Vaccine as Measured by a Hemagglutination Inhibition (HI) Assay Titer of ≥ 1:40 in ≥ 2 of 3 Influenza Antigens at Vaccine Sub-study Visit 3 and 4</title>
          <description>Number (%) of participants achieving protective antibody titers to the seasonal influenza vaccine as measured by an HAI assay titer of ≥1:40 in ≥2 of 3 influenza antigens measured at vaccine sub-study visits 3 and 4.
The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="45.2" upper_limit="66.4"/>
                    <measurement group_id="O2" value="69.2" lower_limit="58.7" upper_limit="78.5"/>
                    <measurement group_id="O3" value="75.0" lower_limit="64.9" upper_limit="83.4"/>
                    <measurement group_id="O4" value="82.4" lower_limit="73.0" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 12 Pneumococcal Antigens as Defined by ≥ 2-fold Increase in Antibody Concentrations From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4</title>
        <description>Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg BID Continuous</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 12 Pneumococcal Antigens as Defined by ≥ 2-fold Increase in Antibody Concentrations From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4</title>
          <description>Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="64.9" upper_limit="83.4"/>
                    <measurement group_id="O2" value="82.4" lower_limit="73.0" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="42.6" upper_limit="63.7"/>
                    <measurement group_id="O2" value="71.4" lower_limit="61.0" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" lower_limit="66.1" upper_limit="84.4"/>
                    <measurement group_id="O2" value="76.9" lower_limit="66.9" upper_limit="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="32.1" upper_limit="53.1"/>
                    <measurement group_id="O2" value="49.5" lower_limit="38.8" upper_limit="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" lower_limit="38.3" upper_limit="59.6"/>
                    <measurement group_id="O2" value="56" lower_limit="45.2" upper_limit="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="61.4" upper_limit="80.6"/>
                    <measurement group_id="O2" value="78" lower_limit="68.1" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" lower_limit="53.5" upper_limit="73.9"/>
                    <measurement group_id="O2" value="78" lower_limit="68.1" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="61.4" upper_limit="80.6"/>
                    <measurement group_id="O2" value="75.8" lower_limit="65.7" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="63.7" upper_limit="82.5"/>
                    <measurement group_id="O2" value="83.5" lower_limit="74.3" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" lower_limit="43.6" upper_limit="64.8"/>
                    <measurement group_id="O2" value="56.0" lower_limit="45.2" upper_limit="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="50.1" upper_limit="70.9"/>
                    <measurement group_id="O2" value="71.4" lower_limit="61.0" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="42.6" upper_limit="63.7"/>
                    <measurement group_id="O2" value="70.3" lower_limit="59.8" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 3 Influenza Antigens as Defined by ≥ 4-fold Increase in Antibody Titers From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4</title>
        <description>Number (%) of participants achieving a satisfactory humoral response to the seasonal influenza vaccine defined as ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2).
The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg BID Continuous Visit 4</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted Visit 4</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 3 Influenza Antigens as Defined by ≥ 4-fold Increase in Antibody Titers From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4</title>
          <description>Number (%) of participants achieving a satisfactory humoral response to the seasonal influenza vaccine defined as ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2).
The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.
95% CI is based on Clopper-Pearson exact method for response rate.</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antigen B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" lower_limit="35.2" upper_limit="56.4"/>
                    <measurement group_id="O2" value="51.6" lower_limit="40.9" upper_limit="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antigen H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="61.4" upper_limit="80.6"/>
                    <measurement group_id="O2" value="63.7" lower_limit="53.0" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antigen H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" lower_limit="55.7" upper_limit="75.8"/>
                    <measurement group_id="O2" value="74.7" lower_limit="64.5" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Fold Increase of Anti-pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4</title>
        <description>Geometric Mean Fold Increase From Baseline of Pneumococcal Antigens Measured at Visit 4.
n was the number of participants with valid and determinate assay results for the specified serotype at the given visit.
The stated number of participants analyzed was the total number of participants. The actual number of participants analyzed for some serotypes varied, and is provided where it differed from the total number of participants.
Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg Continuous</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Fold Increase of Anti-pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4</title>
          <description>Geometric Mean Fold Increase From Baseline of Pneumococcal Antigens Measured at Visit 4.
n was the number of participants with valid and determinate assay results for the specified serotype at the given visit.
The stated number of participants analyzed was the total number of participants. The actual number of participants analyzed for some serotypes varied, and is provided where it differed from the total number of participants.
Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Fold Change in Antibody Level</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" lower_limit="4.57" upper_limit="7.55"/>
                    <measurement group_id="O2" value="9.26" lower_limit="6.89" upper_limit="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" lower_limit="1.97" upper_limit="2.79"/>
                    <measurement group_id="O2" value="4.20" lower_limit="3.31" upper_limit="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" lower_limit="4.22" upper_limit="6.71"/>
                    <measurement group_id="O2" value="6.29" lower_limit="4.65" upper_limit="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.75" upper_limit="2.34"/>
                    <measurement group_id="O2" value="2.53" lower_limit="2.12" upper_limit="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" lower_limit="1.98" upper_limit="2.73"/>
                    <measurement group_id="O2" value="3.06" lower_limit="2.53" upper_limit="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" lower_limit="3.73" upper_limit="5.90"/>
                    <measurement group_id="O2" value="6.41" lower_limit="4.97" upper_limit="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" lower_limit="2.70" upper_limit="3.72"/>
                    <measurement group_id="O2" value="4.39" lower_limit="3.62" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" lower_limit="4.00" upper_limit="6.86"/>
                    <measurement group_id="O2" value="7.34" lower_limit="5.50" upper_limit="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" lower_limit="3.28" upper_limit="4.79"/>
                    <measurement group_id="O2" value="7.41" lower_limit="5.77" upper_limit="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.99" upper_limit="2.72"/>
                    <measurement group_id="O2" value="2.93" lower_limit="2.46" upper_limit="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" lower_limit="2.44" upper_limit="3.62"/>
                    <measurement group_id="O2" value="4.60" lower_limit="3.64" upper_limit="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="2.27" upper_limit="3.32"/>
                    <measurement group_id="O2" value="4.54" lower_limit="3.58" upper_limit="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Fold Increase of Anti-influenza Antibody Levels to Each of the 3 Influenza Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4</title>
        <description>Geometric Mean Fold Increase From Baseline of Influenza Antigens Measured at Visit 4.
n was the number of participants with valid and determinate assay results for the specified HAI strain at the given visit.
Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg BID Continuous</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Fold Increase of Anti-influenza Antibody Levels to Each of the 3 Influenza Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4</title>
          <description>Geometric Mean Fold Increase From Baseline of Influenza Antigens Measured at Visit 4.
n was the number of participants with valid and determinate assay results for the specified HAI strain at the given visit.
Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Fold Change in Antibody Level</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antigen B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="2.57" upper_limit="4.32"/>
                    <measurement group_id="O2" value="4.17" lower_limit="3.25" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antigen H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" lower_limit="5.96" upper_limit="10.58"/>
                    <measurement group_id="O2" value="6.71" lower_limit="4.94" upper_limit="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antigen H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.80" lower_limit="5.58" upper_limit="10.91"/>
                    <measurement group_id="O2" value="8.51" lower_limit="6.45" upper_limit="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Concentrations of Anti-pneumococcal Antibodies at Vaccine Sub-study Visit 3 and 4</title>
        <description>Mean pneumococcal concentrations (ug/mL) at vaccine baseline (visit 2) and post-vaccination visits (visits 3 and 4) by serotype. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed for each serotype varied, and is provided for each individually.
ug/mL=micrograms per milliliter</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg BID Continuous Visit 2</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted Visit 2</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
          <group group_id="O3">
            <title>Tofacitinib 10 mg BID Continuous Visit 3</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O4">
            <title>Tofacitinib 10 mg BID Interrupted Visit 3</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
          <group group_id="O5">
            <title>Tofacitinib 10 mg BID Continuous Visit 4</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O6">
            <title>Tofacitinib 10 mg BID Interrupted Visit 4</title>
            <description>Patients whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Concentrations of Anti-pneumococcal Antibodies at Vaccine Sub-study Visit 3 and 4</title>
          <description>Mean pneumococcal concentrations (ug/mL) at vaccine baseline (visit 2) and post-vaccination visits (visits 3 and 4) by serotype. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed for each serotype varied, and is provided for each individually.
ug/mL=micrograms per milliliter</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Concentration (ug/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="1.08" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.12" lower_limit="0.89" upper_limit="1.42"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.64" upper_limit="2.44"/>
                    <measurement group_id="O4" value="2.26" lower_limit="1.78" upper_limit="2.87"/>
                    <measurement group_id="O5" value="4.16" lower_limit="3.29" upper_limit="5.27"/>
                    <measurement group_id="O6" value="4.80" lower_limit="3.75" upper_limit="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.79" upper_limit="2.98"/>
                    <measurement group_id="O2" value="2.05" lower_limit="1.59" upper_limit="2.63"/>
                    <measurement group_id="O3" value="4.02" lower_limit="3.04" upper_limit="5.32"/>
                    <measurement group_id="O4" value="5.03" lower_limit="3.77" upper_limit="6.71"/>
                    <measurement group_id="O5" value="12.09" lower_limit="8.76" upper_limit="16.69"/>
                    <measurement group_id="O6" value="15.01" lower_limit="10.80" upper_limit="20.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.86" upper_limit="1.36"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.70" upper_limit="1.14"/>
                    <measurement group_id="O3" value="1.81" lower_limit="1.43" upper_limit="2.29"/>
                    <measurement group_id="O4" value="2.41" lower_limit="1.82" upper_limit="3.18"/>
                    <measurement group_id="O5" value="4.27" lower_limit="3.34" upper_limit="5.47"/>
                    <measurement group_id="O6" value="6.61" lower_limit="5.01" upper_limit="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="0.92" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.18" lower_limit="0.89" upper_limit="1.58"/>
                    <measurement group_id="O3" value="1.61" lower_limit="1.25" upper_limit="2.08"/>
                    <measurement group_id="O4" value="2.17" lower_limit="1.61" upper_limit="2.91"/>
                    <measurement group_id="O5" value="3.52" lower_limit="2.60" upper_limit="4.76"/>
                    <measurement group_id="O6" value="5.47" lower_limit="3.98" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="92"/>
                    <count group_id="O6" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.01" upper_limit="1.56"/>
                    <measurement group_id="O2" value="1.16" lower_limit="0.93" upper_limit="1.44"/>
                    <measurement group_id="O3" value="1.80" lower_limit="1.44" upper_limit="2.25"/>
                    <measurement group_id="O4" value="2.24" lower_limit="1.75" upper_limit="2.88"/>
                    <measurement group_id="O5" value="3.44" lower_limit="2.66" upper_limit="4.44"/>
                    <measurement group_id="O6" value="5.27" lower_limit="3.96" upper_limit="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Sub-study. Titers of Anti-influenza Antibodies at Vaccine Sub-study Visit 3 and 4</title>
        <description>Mean influenza antibody titers at visits 3 and 4.</description>
        <time_frame>From vaccine sub-study visit 2 (baseline) to sub-study visit 4</time_frame>
        <population>Evaluable Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg BID Continuous Visit 2</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID Interrupted Visit 2</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
          <group group_id="O3">
            <title>Tofacitinib 10 mg BID Continuous Visit 3</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O4">
            <title>Tofacitinib 10 mg BID Interrupted Visit 3</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
          <group group_id="O5">
            <title>Tofacitinib 10 mg BID Continuous Visit 4</title>
            <description>Participants receiving continuous tofacitinib treatment</description>
          </group>
          <group group_id="O6">
            <title>Tofacitinib 10 mg BID Interrupted Visit 4</title>
            <description>Participants whose treatment with tofacitinib was interrupted for 2 weeks post-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Sub-study. Titers of Anti-influenza Antibodies at Vaccine Sub-study Visit 3 and 4</title>
          <description>Mean influenza antibody titers at visits 3 and 4.</description>
          <population>Evaluable Immunogenicity Population</population>
          <units>Antibody Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAI B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.43" lower_limit="9.38" upper_limit="13.91"/>
                    <measurement group_id="O2" value="10.85" lower_limit="8.90" upper_limit="13.22"/>
                    <measurement group_id="O3" value="23.29" lower_limit="17.92" upper_limit="30.27"/>
                    <measurement group_id="O4" value="37.45" lower_limit="28.17" upper_limit="49.78"/>
                    <measurement group_id="O5" value="38.06" lower_limit="28.71" upper_limit="50.47"/>
                    <measurement group_id="O6" value="45.19" lower_limit="35.01" upper_limit="58.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAI H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.14" lower_limit="11.67" upper_limit="19.64"/>
                    <measurement group_id="O2" value="20.26" lower_limit="14.86" upper_limit="27.62"/>
                    <measurement group_id="O3" value="52.75" lower_limit="37.97" upper_limit="73.28"/>
                    <measurement group_id="O4" value="105.2" lower_limit="70.76" upper_limit="156.5"/>
                    <measurement group_id="O5" value="120.2" lower_limit="89.83" upper_limit="160.8"/>
                    <measurement group_id="O6" value="136.0" lower_limit="97.67" upper_limit="189.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAI H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.18" lower_limit="13.53" upper_limit="24.44"/>
                    <measurement group_id="O2" value="17.30" lower_limit="12.98" upper_limit="23.07"/>
                    <measurement group_id="O3" value="55.07" lower_limit="38.19" upper_limit="79.43"/>
                    <measurement group_id="O4" value="83.10" lower_limit="57.38" upper_limit="120.4"/>
                    <measurement group_id="O5" value="141.8" lower_limit="102.9" upper_limit="195.4"/>
                    <measurement group_id="O6" value="147.2" lower_limit="107.8" upper_limit="201.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>114 months</time_frame>
      <desc>Events listed by Preferred Term. Includes data up to 999 days after last dose of study medication</desc>
      <group_list>
        <group group_id="E1">
          <title>Tofacitinib 5 Milligram (mg) Twice Daily (BID)</title>
          <description>Participants with non-zero average total daily dose across study &lt;15 were assigned to 5 mg BID</description>
        </group>
        <group group_id="E2">
          <title>Tofacitinib 10 mg BID</title>
          <description>Participants with average total daily dose across study &gt;/=15 were assigned to 10 mg BID</description>
        </group>
        <group group_id="E3">
          <title>All Tofacitinib</title>
          <description>All participants treated with tofacitinib from 5 mg BID and 10 mg BID groups</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="346" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="997" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1343" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Mastocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Paratracheal lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Long QT syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tourette’s disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Keratitis interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Necrotising retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Optic disc drusen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Crohn’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Enterocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fistula of small intestine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abscess sterile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cholangitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gallbladder non-functioning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sphincter of Oddi dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bartholin’s abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Eye infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Herpes dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Herpes zoster cutaneous disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Infective spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Meningococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Peritoneal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonia cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Primary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pyoderma streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sinusitis aspergillus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tuberculosis of central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Exposure via father</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Foetal exposure during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint dislocation postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Maternal exposure timing unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Post procedural oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Twiddler’s syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Airway peak pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>B-lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Human papilloma virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metamyelocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Myelocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia unawareness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired claw toe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Atlantoaxial instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Dupuytren’s contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Extraskeletal ossification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Finger deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hand deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ligament disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rheumatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Synovial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tendon calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>5q minus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>B-cell small lymphocytic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Benign tracheal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Choroid plexus papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Endometrial cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hodgkin’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Kaposi’s sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Marginal zone lymphoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Medullary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Mucoepidermoid carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Nodular melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin’s lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sebaceous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spindle cell sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Synovial sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tumour necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ureteral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Vulval cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Intensive care unit acquired weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pachymeningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Parkinson’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Small fibre neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spinal subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Device electrical impedance issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Mixed incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ureteral necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Breast hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Endometrial dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Fallopian tube cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute interstitial pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Respiration abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Activities of daily living impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Physical abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Thromboangiitis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="807" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="2422" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="3229" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="240" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="285" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="231" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="430" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="571" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="373" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="490" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="277" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="517" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="655" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="206" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="309" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="613" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="841" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="447" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="608" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="273" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="185" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="247" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="338" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="176" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="215" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="265" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="352" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="291" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="397" subjects_at_risk="4481"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="396" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="268" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="202" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="267" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="1123"/>
                <counts group_id="E2" subjects_affected="311" subjects_at_risk="3358"/>
                <counts group_id="E3" subjects_affected="450" subjects_at_risk="4481"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the investigator is that the sponsor can review results communications at least 30 days prior to public release and can embargo communications regarding trial results for a period that is no more than an additional 60 days. Investigators will, on request, remove any previously undisclosed confidential information (other than the study results themselves) before disclosure.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All information is based on protocol Amendment 25 with a database release date of 02 March 2017.
One serious adverse event in the Tofacitinib 5mg BID group could not be coded (&quot;septic shock and pneumonia&quot;) and has not been included.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

